{"gene":"PF4","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2004,"finding":"PF4 tetramers and unfractionated heparin form ultralarge complexes (>670 kDa) over a narrow molar ratio (~1:1 PF4:heparin); these ultralarge complexes are more reactive toward HIT-like monoclonal antibodies and promote greater FcγRIIA-dependent platelet activation than smaller complexes. Formation of ultralarge complexes required intact PF4 tetramers (demonstrated by mutation studies) and did not occur with low-molecular-weight heparin or fondaparinux.","method":"Electron microscopy, size-exclusion chromatography, mutagenesis of PF4 tetramerization, platelet activation assays, antibody-binding assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with defined components, electron microscopy, mutagenesis, multiple orthogonal functional assays in single rigorous study","pmids":["15304392"],"is_preprint":false},{"year":2000,"finding":"Neutrophil gelatinase B (MMP-9) degrades PF4 (platelet factor 4), in contrast to its potentiating effect on IL-8; PF4 is thus a substrate of MMP-9 proteolysis.","method":"In vitro proteolysis assay with purified human neutrophil progelatinase B activated by stromelysin-1; gel analysis of cleavage products","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro enzyme assay with purified components; rigorous controls comparing multiple chemokines","pmids":["11023497"],"is_preprint":false},{"year":2014,"finding":"Megakaryocytes are the predominant source of CXCL4 in the bone marrow niche; CXCL4 secreted by megakaryocytes directly regulates HSC quiescence. In vivo CXCL4 injection increased HSC quiescence and reduced HSC number, while Cxcl4−/− mice showed increased HSC number and proliferation. 3D whole-mount imaging confirmed HSCs are preferentially located adjacent to megakaryocytes.","method":"In vivo CXCL4 injection, Cxcl4−/− mouse model, selective MK depletion, 3D whole-mount imaging, gene expression analysis, flow cytometry","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO, in vivo gain-of-function, direct imaging, multiple orthogonal methods; replicated across complementary approaches","pmids":["25326802"],"is_preprint":false},{"year":2007,"finding":"CXCL4 is stored in secretory granules and released in response to protein kinase C (PKC) activation, whereas its non-allelic variant CXCL4L1 is continuously secreted via a constitutive pathway. This difference in subcellular localization and regulated secretion was established in multiple transfected cell types and confirmed in lymphocytes (primarily CXCL4) and smooth muscle cells (primarily CXCL4L1).","method":"Transfection of multiple cell types, subcellular fractionation/localization, PKC stimulation assays, secretion pathway analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple cell types, orthogonal localization and secretion assays, comparison with variant chemokine as internal control","pmids":["17218382"],"is_preprint":false},{"year":2011,"finding":"RUNX1 is a direct transcriptional regulator of the PF4 gene. RUNX1 binds to consensus sites at −1774/−1769 and −157/−152 on the PF4 promoter. Mutation of either site markedly reduced promoter activity; RUNX1 knockdown decreased and RUNX1 overexpression increased PF4 promoter activity and protein levels.","method":"Chromatin immunoprecipitation (ChIP), electrophoretic mobility shift assay (EMSA), luciferase reporter assay, siRNA knockdown, RUNX1 overexpression in HEL cells","journal":"Journal of thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP, EMSA, reporter mutagenesis, gain- and loss-of-function in single study","pmids":["21129147"],"is_preprint":false},{"year":2004,"finding":"Upstream stimulatory factors USF1 and USF2 bind E-box motifs in the TME regulatory element of the PF4 promoter and strongly transactivate PF4 expression in megakaryocytic cells; physiological binding of USF1/2 to the TME in rat megakaryocytes was confirmed.","method":"Mass spectrometry identification of promoter-binding proteins, ChIP assay in primary megakaryocytes, luciferase reporter assay, EMSA, RT-PCR","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Strong — ChIP in primary cells, EMSA, reporter assays with defined binding sites, protein identification by MS","pmids":["15187018"],"is_preprint":false},{"year":2019,"finding":"CXCL4 organizes self-DNA and microbial DNA into liquid crystalline immune complexes that amplify TLR9-mediated plasmacytoid dendritic cell hyperactivation and interferon-α production. This activity does not require CXCR3. CXCL4-DNA complexes were detected in vivo in SSc blood and correlated with the type I IFN signature.","method":"Biophysical characterization (liquid crystalline complex formation), in vitro pDC stimulation assays, CXCR3 blocking/knockout experiments, detection of complexes in patient plasma, skin pDC immunostaining","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — biophysical reconstitution, multiple cell-based assays, receptor-independence demonstrated by blocking and KO, in vivo patient samples","pmids":["31043596"],"is_preprint":false},{"year":2009,"finding":"CXCL4 directly downregulates CD163 (hemoglobin-haptoglobin scavenger receptor) expression on human macrophages differentiated from monocytes, resulting in inability to upregulate heme oxygenase-1 in response to hemoglobin-haptoglobin complexes. CXCL4's effect was neutralized by heparin (which binds CXCL4) and blocked by chlorate pretreatment (inhibiting glycosaminoglycan synthesis), indicating CXCL4 acts through cell-surface glycosaminoglycans.","method":"Flow cytometry, mRNA quantification (time-course), heparin neutralization, chlorate inhibition of GAG synthesis, platelet releasate experiments, immunofluorescence of human plaques","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods, mechanism-of-action dissected by receptor/GAG blockade, in vivo correlation in human tissue","pmids":["19910578"],"is_preprint":false},{"year":2018,"finding":"CXCL4 is an agonist of CCR1 and drives chemotaxis of primary human monocytes through CCR1. CXCL4-induced migration and calcium responses in THP-1 cells were pertussis toxin-sensitive (implying Gi-coupled GPCR), abrogated by chondroitinase ABC (requiring cell-surface GAG presentation), insensitive to CXCR3 antagonist, and inhibited by a CCR1 antagonist. CXCL4 also induced CCR1 endocytosis.","method":"Chemotaxis assays, intracellular calcium measurements, pertussis toxin treatment, chondroitinase ABC treatment, CCR1-transfectant migration assays, CCR1 endocytosis assay, CCR1 antagonist inhibition","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods, receptor identified by transfectant assays, confirmed in primary human monocytes with pharmacological inhibition","pmids":["29930254"],"is_preprint":false},{"year":2005,"finding":"CXCL4 and CXCL10 exert opposite effects on human TH1/TH2 cytokine production via their respective interactions with CXCR3-B and CXCR3-A. CXCL4 downregulates IFN-γ and upregulates TH2 cytokines (IL-4, IL-5, IL-13), downregulates T-bet, upregulates GATA-3, and induces direct activation of IL-5 and IL-13 promoters. These effects were blocked by anti-CXCR3 antibody.","method":"Quantitative RT-PCR, flow cytometry, ELISA on antigen-specific and polyclonally activated T-cell lines, anti-CXCR3 blocking antibody, IL-5/IL-13 promoter activation assays","journal":"The Journal of allergy and clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (qPCR, ELISA, promoter assays, blocking Ab), single laboratory","pmids":["16337473"],"is_preprint":false},{"year":2008,"finding":"CXCL4 interacts with αvβ3, αvβ5, and α5β1 integrins on human endothelial cells. Immobilized CXCL4 supports endothelial cell adhesion, spreading, and migration in an integrin-dependent manner, whereas soluble CXCL4 inhibits integrin-dependent adhesion and migration, contributing to its anti-angiogenic effect.","method":"Cell adhesion assays with integrin-transfected CHO cells, HUVEC adhesion/spreading/migration assays, integrin-blocking antibodies","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cell assays with blocking antibodies, multiple integrin receptors tested, single laboratory","pmids":["18648521"],"is_preprint":false},{"year":2008,"finding":"CXCL4 binds to chondroitin sulfate proteoglycans on neutrophil surfaces; immune complexes of PF4 and anti-PF4 antibodies colocalize with CD32a (FcγRIIA) on neutrophils and activate neutrophils (~3-fold increase in Mac-1 expression, degranulation, enhanced adhesion). Chondroitinase ABC treatment blocked PF4 binding and cell activation. Arginine 49 of PF4 was identified as important for stabilizing PF4-chondroitin binding.","method":"Flow cytometry, confocal microscopy, chondroitinase ABC treatment, anti-CD32/FcγRII blocking antibody, recombinant PF4 mutagenesis (Arg49), degranulation assays, cell adhesion assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — site-directed mutagenesis identifying key residue, multiple orthogonal functional assays, receptor colocalization by confocal microscopy","pmids":["18539895"],"is_preprint":false},{"year":2012,"finding":"PF4/heparin antibody complexes induce monocyte tissue factor (TF) expression and release of TF-positive microparticles via engagement of FcγRI receptor and activation of the MEK1-ERK1/2 signaling pathway, providing a mechanism for thrombosis in HIT.","method":"Ex vivo monocyte stimulation with monoclonal anti-PF4/heparin antibody (KKO) and HIT patient plasma, TF expression assays, microparticle quantification, FcγRI blocking, MEK1-ERK1/2 pathway inhibition","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — specific receptor and signaling pathway identified by blocking/inhibition, validated with both monoclonal antibody and patient sera","pmids":["22394597"],"is_preprint":false},{"year":2005,"finding":"PF4/heparin complexes are T cell-dependent antigens. Euthymic mice immunized with mPF4/heparin complexes (but not mPF4 or heparin alone) developed heparin-dependent autoantibodies with HIT-like characteristics; athymic mice did not develop these antibodies.","method":"Murine immunization model, euthymic vs. athymic mice comparison, platelet activation assay, antibody binding assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic model (athymic mice), antigen specificity controls, functional antibody characterization","pmids":["15845897"],"is_preprint":false},{"year":2015,"finding":"CD4 T cells are required for production of PF4/heparin-specific antibodies. Depletion of CD4 T cells markedly impaired PF4/heparin-specific antibody induction; reconstitution experiments showed T-cell help is necessary; B cells lacking CD40 showed markedly reduced PF4/heparin-specific antibody production, demonstrating CD40-dependent T-B cell cooperation.","method":"CD4 T-cell depletion with anti-CD4 antibody, Rag1−/− reconstitution with B cells ± T cells, B cell-specific CD40 knockout mice, ELISA for specific antibodies","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (depletion, KO, reconstitution), mechanistic dissection of T-B cooperation","pmids":["25595736"],"is_preprint":false},{"year":2011,"finding":"CXCL4 signaling via CXCR3-B activates Gs proteins, elevates cAMP, and activates p38 MAP kinase. Signaling via chondroitin sulfate proteoglycans involves Src family kinases, Syk, monomeric GTPases (including Rac2), sphingosine kinase 1, and MAP kinase family members, with biphasic kinetics of Rac2 and SphK1 activation in monocytes and neutrophils.","method":"Pharmacological inhibitors, kinase activation assays, receptor-specific experiments (CXCR3-B vs. proteoglycan), review/synthesis of multiple experimental studies","journal":"European journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — synthesis of multiple experimental studies from the field; individual components each from single studies","pmids":["21295372"],"is_preprint":false},{"year":2010,"finding":"CXCL4 induces down-regulation of CC chemokine receptors CCR1, CCR2, and CCR5 on human monocytes through autocrine/paracrine TNF-α release; TNF-α then induces CCL3 and CCL4 secretion (desensitizing CCR1 and CCR5), while CCL2 secretion was TNF-α-independent. This limits monocyte chemotactic migration toward cognate CC chemokine ligands.","method":"Flow cytometry for CCR expression, TNF-α neutralization, chemotaxis assays, cytokine measurements, conditioned medium experiments","journal":"Innate immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic dissection with neutralization and downstream readouts, single laboratory, multiple methods","pmids":["21088050"],"is_preprint":false},{"year":2010,"finding":"Sphingosine kinase 1 (SphK1) is a central regulator of CXCL4-induced monocyte survival, cytokine expression, and oxygen radical formation. CXCL4 upregulates SphK1 mRNA, induces SphK1 enzyme activity, and causes its translocation to the cell membrane. Pharmacological SphK inhibition and SphK1-specific siRNA reversed CXCL4-induced monocyte survival, cytokine expression, and ROS release; the anti-apoptotic effect involves SphK1-dependent caspase inhibition and Erk activation.","method":"SphK activity assay, SphK1 membrane translocation assay, pharmacological SphK inhibitor, siRNA knockdown, apoptosis/caspase assays, cytokine and ROS measurements","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — enzyme activity, translocation, siRNA confirmation, pharmacological inhibition; single laboratory, multiple orthogonal methods","pmids":["20104488"],"is_preprint":false},{"year":2009,"finding":"CXCL4 protects the antimicrobial peptide LL-37 from cleavage by mast cell beta-tryptase. CXCL4 does not directly inhibit beta-tryptase but destabilizes active tetrameric beta-tryptase by antagonizing the heparin component required for tetramer integrity, thereby acting as a counter-regulator of tryptase activity.","method":"In vitro protease cleavage assays, inhibitor studies, comparison of tryptase tetramer stability, bactericidal/functional assays of LL-37 fragments","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro enzyme assay with mechanistic dissection (heparin competition), single laboratory","pmids":["19625657"],"is_preprint":false},{"year":2008,"finding":"Brain microglia express CXCL4 in vitro and in vivo under neurodegenerating conditions. CXCL4-induced microglial migration is absent in CXCR3-deficient microglia, indicating CXCR3 mediates this response. CXCL4 also attenuates LPS-induced microglial phagocytosis and nitric oxide production.","method":"In vitro microglia culture, CXCR3−/− microglia migration assays, in vivo immunohistochemistry, phagocytosis and NO production assays","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO for receptor identification, multiple functional readouts, single laboratory","pmids":["18248618"],"is_preprint":false},{"year":2015,"finding":"Platelet secretion of CXCL4 in sepsis is Rac1-dependent. Rac1 inhibitor NSC23766 decreased CLP-enhanced plasma CXCL4 by 77% and abolished PAR4 agonist-induced CXCL4 secretion from isolated platelets. CXCL4 promotes neutrophil accumulation in the lung indirectly by inducing CXCL2 production from alveolar macrophages; CXCL4 itself did not directly drive neutrophil chemotaxis in vitro.","method":"Murine CLP sepsis model, Rac1 inhibitor, platelet depletion, ELISA for CXCL4/CXCL2, CXCR2 antagonist, in vitro neutrophil chemotaxis assay, alveolar macrophage stimulation","journal":"British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection of secretion mechanism and downstream pathway, in vivo and in vitro validation, single laboratory","pmids":["26478565"],"is_preprint":false},{"year":2021,"finding":"C5a activation of C5aR1 on platelets drives preferential release of CXCL4 as an antiangiogenic effector molecule. Platelet-specific deletion of C5aR1 produced a proangiogenic phenotype; interfering with the C5aR1-CXCL4 axis reversed the antiangiogenic effect of platelets both in vitro and in vivo.","method":"C5ar1−/− mice, platelet-specific C5aR1 deletion, in vitro endothelial cell migration and tube formation assays, in vivo vascularization models, CXCL4 measurement","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — platelet-specific genetic KO, multiple in vitro and in vivo functional assays, mechanistic axis identified","pmids":["34099640"],"is_preprint":false},{"year":2023,"finding":"CXCL4 binds glycosaminoglycan (GAG) sugars on proteoglycans within the endothelial extracellular matrix, resulting in increased leukocyte adhesion, increased vascular permeability, and non-specific recruitment of a range of leukocytes independent of classical chemokine receptors. GAG sulfation confers selectivity onto chemokine localization.","method":"Biophysical binding assays, in vitro leukocyte adhesion and vascular permeability assays, in vivo leukocyte recruitment, GAG-binding mutants","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — biophysical, in vitro, and in vivo methods combined, receptor-independent mechanism demonstrated","pmids":["36640356"],"is_preprint":false},{"year":2018,"finding":"In human monocytes/macrophages, costimulation by CXCL4 and TLR8 synergistically activates TBK1 and IKKε, repurposes these kinases toward inflammatory response via coupling with IRF5, and activates the NLRP3 inflammasome. CXCL4 + TLR8 costimulation induces chromatin remodeling and activates de novo enhancers associated with inflammatory genes, selectively amplifying IL-1β production while partially attenuating the interferon response.","method":"Kinase activation assays (TBK1, IKKε), IRF5 coupling assays, NLRP3 inflammasome activation, epigenomic profiling (ATAC-seq/ChIP), gene expression analysis, IL-1β ELISA","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — mechanistic pathway dissection with multiple orthogonal methods including epigenomics, kinase activation, and inflammasome assays","pmids":["35701499"],"is_preprint":false},{"year":2024,"finding":"PF4 binds and activates the thrombopoietin receptor c-Mpl on platelets, leading to JAK2 activation and phosphorylation of STAT3 and STAT5, resulting in platelet aggregation. Inhibition of the c-Mpl-JAK2 pathway inhibits platelet aggregation induced by PF4 alone, VITT sera, and PF4 combined with VITT IgG. PF4-based immune complexes activate platelets through both FcγRIIA (Fc domain) and c-Mpl (PF4 domain).","method":"Binding assays (PF4 to c-Mpl), JAK2/STAT3/STAT5 phosphorylation assays, c-Mpl-JAK2 pathway inhibition, platelet aggregation assays with VITT sera and patient IgG","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — receptor binding, downstream signaling cascade defined, pharmacological inhibition, patient-derived functional validation","pmids":["37883794"],"is_preprint":false},{"year":2019,"finding":"CXCL4 forms heterodimers with CXCL12; the CXCL4-CXCL12 binding interface was identified by NMR spectroscopy. CXCL4-CXCL12 heterodimers inhibit CXCL12-driven breast cancer cell migration via CXCR4. A CXCL4-derived peptide mimicking the binding interface reproduced this inhibitory activity.","method":"NMR spectroscopy (binding interface mapping), cell migration assays (MDA-MB-231), CXCR4 blocking, CXCL4-derived peptide functional assay","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — NMR structural mapping of binding interface, functional validation in migration assay, single laboratory","pmids":["31785332"],"is_preprint":false},{"year":1989,"finding":"PF4 inhibits human megakaryocytopoiesis in vitro with lineage specificity (no effect on myeloid or erythroid colony formation). Inhibition was mediated through impeding megakaryocyte maturation rather than proliferation. A synthetic 24-residue COOH-terminal PF4 peptide reproduced this effect and decreased Factor V mRNA expression in individual megakaryocytes (~60% reduction).","method":"Megakaryocyte colony formation assay, cell maturation analysis, in situ hybridization for Factor V mRNA in single cells, comparison with beta-thromboglobulin peptides","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — lineage-specific inhibition, mechanistic dissection (maturation vs. proliferation), peptide domain mapping, single laboratory","pmids":["2523411"],"is_preprint":false},{"year":2016,"finding":"CXCL4 and CXCR2 regulate survival and self-renewal of hematopoietic stem/progenitor cells. CXCL4 knockdown in human CD34+ cells significantly decreased viability and colony-forming potential. Cxcl4−/− mice showed decreased HSC numbers and reduced self-renewal capacity after secondary transplantation, demonstrating an autocrine/paracrine role of CXCL4 in HSC maintenance.","method":"siRNA knockdown in human CD34+ cells, Cxcl4−/− mouse model, serial transplantation assays, flow cytometry for HSC subpopulations, colony formation assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO, human cell knockdown, serial transplantation; multiple orthogonal methods, two species","pmids":["27222476"],"is_preprint":false},{"year":2018,"finding":"Polyreactive natural IgM initiates complement activation by PF4/heparin complexes through the classical complement pathway. Plasma IgM levels correlated with complement activation (r=0.898). IgM depletion abrogated C3c generation. Monoclonal polyreactive IgM and cord blood IgM generated C3c in the presence of PF4/heparin. Anti-C1q antibody prevented IgM-mediated complement activation, confirming classical pathway involvement.","method":"Proteomic correlation analysis, IgM depletion experiments, cord blood IgM, monoclonal polyreactive IgM, anti-C1q blocking, C3c generation assay, B-cell deposition assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (depletion, blocking, reconstitution), mechanistic pathway (classical complement) defined, replicated across donor plasmas","pmids":["30309891"],"is_preprint":false},{"year":2010,"finding":"Cxcl4 genetic deletion in mice significantly reduced liver fibrosis after CCl4 and thioacetamide-induced chronic injury, decreased infiltration of neutrophils and CD8+ T cells, and was associated with changes in fibrosis-related gene expression (Timp-1, Mmp9, Tgf-β, IL-10). In vitro, recombinant Cxcl4 stimulated proliferation, chemotaxis, and chemokine expression of hepatic stellate cells.","method":"Cxcl4−/− mice in two injury models, histological/biochemical analysis, FACS for infiltrating immune cells, in vitro hepatic stellate cell assays, gene expression analysis","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO in two independent injury models, in vitro mechanistic validation in target cells, multiple orthogonal readouts","pmids":["20162727"],"is_preprint":false},{"year":2022,"finding":"CXCL4 directly induces myofibroblast differentiation and collagen synthesis in fibroblast precursors and endothelial cells (through endothelial-to-mesenchymal transition). CXCL4-deficient mice showed reduced fibrosis in skin, lungs, and heart; overexpressing human CXCL4 in mice aggravated bleomycin-induced fibrosis; blocking CXCL4 reduced fibrosis.","method":"Cxcl4−/− mice (multiple fibrotic models), human CXCL4 overexpression mouse model, CXCL4 blocking, in vitro myofibroblast differentiation and collagen synthesis assays, single-cell ligand-receptor analysis","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO, gain-of-function overexpression, pharmacological blocking, in vitro mechanistic validation, multiple organ systems","pmids":["34986347"],"is_preprint":false},{"year":2014,"finding":"CXCL4 activates the p38-MAPK pathway through CXCR3, leading to upregulation of p53 and Bax and subsequent caspase-8, -9, and -3 activation in intestinal epithelial cells (IEC-6), mediating 5-FU-induced intestinal apoptosis. Neutralizing anti-CXCL4 antibody reduced p53 and Bax expression and crypt epithelial apoptosis in vivo.","method":"In vivo 5-FU mucositis mouse model, anti-CXCL4 neutralizing antibody, in vitro IEC-6 signaling (p38-MAPK phosphorylation, p53/Bax expression, caspase activation), CXCR3 receptor identification","journal":"Cancer biology & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — signaling cascade defined in vitro with pharmacological validation, confirmed in vivo with neutralizing antibody, single laboratory","pmids":["24800927"],"is_preprint":false},{"year":2023,"finding":"CXCL4 assembles RNA (in addition to DNA) into complexes that protect RNA from enzymatic degradation and persist in vivo in SSc plasma. CXCL4-RNA complexes stimulate monocyte-derived DCs to produce TNF-α, IL-12, IL-23, IL-8, and pro-collagen in a predominantly TLR7/8-dependent, CXCR3-independent manner.","method":"CXCL4-RNA complex detection in SSc patient plasma, RNase protection assays, in vitro MDDC stimulation, TLR7/8 blocking, CXCR3 blocking, cytokine/collagen measurement","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro mechanistic dissection with receptor blocking, in vivo complex detection in patients, single laboratory","pmids":["36614095"],"is_preprint":false},{"year":2022,"finding":"CXCL4 links inflammation to fibrosis by reprogramming monocyte-derived dendritic cells through key transcriptional regulator CIITA. Inhibition of CIITA mimicked CXCL4's pro-inflammatory/pro-fibrotic phenotype. CXCL4-exposed dendritic cells produce extracellular matrix molecules and induce myofibroblast differentiation.","method":"Transcriptomic and methylation profiling (65 longitudinal profiles), gene regulatory network analysis, CIITA inhibition, in vitro myofibroblast differentiation assay, ECM production measurement","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systems-level analysis validated by CIITA inhibition experiments and functional assays, single laboratory","pmids":["33042127"],"is_preprint":false},{"year":2020,"finding":"CXCL4 production by pDCs in SSc is driven by simultaneous exposure to hypoxia and TLR9 activation, dependent on mitochondrial reactive oxygen species (mtROS) overproduction leading to stabilization of HIF-2α. Blocking either mtROS or HIF-2α pathways attenuated CXCL4 production.","method":"pDC culture under hypoxia ± TLR agonists, mtROS inhibition, HIF-1α/HIF-2α expression and stabilization assays (ELISA, qPCR, FACS, Western blot), umbilical cord CD34-derived pDC validation","journal":"Rheumatology (Oxford)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods, pathway inhibitor validation, single laboratory","pmids":["34559222"],"is_preprint":false},{"year":2020,"finding":"CXCL4 triggers monocytes and macrophages to produce PDGF-BB, which then activates dermal fibroblasts to produce extracellular matrix and inflammatory mediators. This indirect fibroblast activation was abrogated by PDGF-receptor inhibition (Crenolanib or siRNA). TLR ligands, IFNα, and TGFβ did not induce PDGF-BB release in contrast to CXCL4.","method":"Multiplex immunoassay for cytokines, PDGF-BB quantification (immunoassay, Western blot), siRNA PDGF-receptor knockdown, Crenolanib inhibition, fibroblast ECM and cytokine production assays","journal":"Journal of autoimmunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway from CXCL4→PDGF-BB→fibroblast activation defined, pharmacological and genetic blocking, single laboratory","pmids":["32284212"],"is_preprint":false},{"year":2019,"finding":"CXCL4 infusion impaired macrophage phagocytic capacity by reducing CD36 levels through MMP-9-dependent and -independent signaling, leading to higher post-MI mortality and LV dilation. In vitro, a CD36 neutralizing antibody inhibited phagocytosis similarly to CXCL4, and combination of CXCL4 + CD36Ab had no additive effect, establishing CXCL4 acts through CD36 signaling.","method":"In vivo CXCL4 mini-pump infusion post-MI, echocardiography, ex vivo and in vitro phagocytosis assays, CD36 neutralizing antibody, MMP-9 measurement, gene expression analysis","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro mechanistic dissection, receptor identified by non-additivity experiment, single laboratory","pmids":["30169632"],"is_preprint":false},{"year":1975,"finding":"PF4 (platelet factor 4) is a heat-stable heparin-neutralizing protein purified from human platelets; its antiheparin activity and antigenicity are destroyed by trypsin; PF4 forms a complex with heparin that shifts its electrophoretic migration from cathodal to anodal, indicating charge neutralization.","method":"SDS-PAGE, immunodiffusion, immunoelectrophoresis with monospecific antibody, heparin-neutralization assay, trypsin digestion, antibody inhibition of antiheparin activity","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct biochemical characterization with purified protein, multiple complementary methods, foundational study","pmids":["803847"],"is_preprint":false},{"year":2023,"finding":"Platelets are activated by exercise and are required for exercise-induced hippocampal precursor cell proliferation in aged mice. The platelet-derived exerkine CXCL4/PF4 ameliorates age-related regenerative and cognitive impairments in a hippocampal neurogenesis-dependent manner when administered systemically.","method":"Platelet depletion during exercise, aged mouse model, hippocampal precursor cell proliferation assay, systemic CXCL4 injection, hippocampal neurogenesis-dependent cognitive testing","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — platelet depletion and CXCL4 injection with neurogenesis-dependent functional readout, single laboratory","pmids":["37587147"],"is_preprint":false}],"current_model":"PF4/CXCL4 is a highly cationic CXC chemokine stored in platelet α-granules and secreted upon PKC-dependent platelet activation (regulated by Rac1); it forms tetramers that assemble with heparin or other polyanions into ultralarge antigenic complexes (central to HIT pathogenesis via FcγRIIA- and c-Mpl/JAK2-mediated platelet activation); it binds cell-surface glycosaminoglycans (chondroitin sulfate proteoglycans) and integrins (αvβ3, αvβ5, α5β1) to exert context-dependent effects including macrophage differentiation to a unique CD163-negative 'M4' phenotype, induction of monocyte survival and pro-fibrotic PDGF-BB release, direct myofibroblast differentiation and collagen synthesis, inhibition of angiogenesis, regulation of HSC quiescence via megakaryocyte-derived secretion, induction of neutrophil accumulation through indirect CXCL2 generation in macrophages, amplification of TLR9 and TLR8 innate immune responses by forming liquid-crystalline DNA/RNA complexes, and inhibition of T cell-mediated immune responses through CXCR3-dependent suppression of CD8+ T cells; its transcription in megakaryocytes is directly regulated by RUNX1 (binding −1774 and −157 promoter sites) and by USF1/USF2 (binding E-box/TME elements), and its production in pDCs is driven by hypoxia+TLR9 costimulation via mtROS-HIF-2α stabilization."},"narrative":{"mechanistic_narrative":"PF4/CXCL4 is a highly cationic, heparin-neutralizing CXC chemokine stored in platelet secretory granules whose biological output is dominated by its capacity to bind polyanions and assemble into multivalent complexes that drive immune, hematopoietic, fibrotic, and vascular responses [PMID:803847, PMID:15304392, PMID:17218382]. As a foundational property, PF4 forms charge-neutralizing complexes with heparin [PMID:803847], and intact PF4 tetramers assemble with unfractionated heparin into ultralarge (>670 kDa) complexes over a narrow molar ratio that are the principal antigenic targets in heparin-induced thrombocytopenia and drive FcγRIIA-dependent platelet activation [PMID:15304392]. These complexes behave as T cell-dependent antigens requiring CD4 T-cell help and CD40-dependent T-B cooperation [PMID:15845897, PMID:25595736], and the resulting PF4/heparin antibodies propagate thrombotic signaling by inducing monocyte tissue factor via FcγRI-MEK1-ERK1/2 [PMID:22394597], engaging FcγRIIA on neutrophils bound to surface chondroitin sulfate [PMID:18539895], and triggering classical-pathway complement activation through polyreactive natural IgM [PMID:30309891]; PF4 itself also activates platelets directly by binding the thrombopoietin receptor c-Mpl, activating JAK2 and STAT3/STAT5 [PMID:37883794]. Beyond complex formation, secreted PF4 acts through multiple cell-surface platforms: cell-surface glycosaminoglycans and chondroitin sulfate proteoglycans [PMID:19910578, PMID:18539895, PMID:36640356], integrins αvβ3/αvβ5/α5β1 on endothelium where soluble PF4 inhibits adhesion and angiogenesis [PMID:18648521, PMID:34099640], the GPCRs CXCR3 and CCR1 [PMID:16337473, PMID:29930254], and CD36 on macrophages [PMID:30169632]. Through these receptors PF4 reprograms myeloid cells—downregulating CD163 on macrophages [PMID:19910578], driving monocyte survival and cytokine output via sphingosine kinase 1 [PMID:20104488], and synergizing with TLR8 to activate TBK1/IKKε-IRF5 and the NLRP3 inflammasome [PMID:35701499]—and organizes self- and microbial DNA and RNA into liquid-crystalline complexes that amplify TLR9 and TLR7/8 responses in dendritic cells, a mechanism central to systemic sclerosis pathology [PMID:31043596, PMID:36614095]. PF4 is a potent pro-fibrotic effector, directly inducing myofibroblast differentiation and collagen synthesis and promoting fibrosis across skin, lung, heart, and liver [PMID:34986347, PMID:20162727], partly via monocyte-derived PDGF-BB [PMID:32284212]. As a megakaryocyte- and platelet-derived niche factor it enforces HSC quiescence and supports HSC self-renewal [PMID:25326802, PMID:27222476]. Megakaryocytic PF4 transcription is directly controlled by RUNX1 and by USF1/USF2 acting on E-box/TME promoter elements [PMID:21129147, PMID:15187018].","teleology":[{"year":1975,"claim":"Established PF4's defining biochemical identity as a heparin-neutralizing platelet protein, framing all later polyanion-driven mechanisms.","evidence":"Purification from human platelets with immunoelectrophoresis, heparin-neutralization assay, and trypsin digestion","pmids":["803847"],"confidence":"Medium","gaps":["No structural basis for tetramerization or heparin binding defined","Cellular receptors not yet identified"]},{"year":1989,"claim":"Showed PF4 has lineage-specific autoregulatory effects on its own producer lineage, inhibiting megakaryocyte maturation.","evidence":"Megakaryocyte colony formation assays, in situ hybridization for Factor V mRNA, COOH-terminal peptide mapping","pmids":["2523411"],"confidence":"Medium","gaps":["Receptor mediating the inhibition not identified","Relationship to later HSC quiescence role unestablished"]},{"year":2000,"claim":"Identified MMP-9 as a protease that degrades PF4, distinguishing its regulation from other chemokines and indicating proteolytic turnover.","evidence":"In vitro proteolysis assay with purified neutrophil progelatinase B activated by stromelysin-1","pmids":["11023497"],"confidence":"High","gaps":["Cleavage sites and biological consequences of fragments not defined"]},{"year":2004,"claim":"Defined the molecular requirements for the antigenic PF4/heparin complex in HIT, explaining why only certain heparins and intact tetramers are pathogenic.","evidence":"Electron microscopy, size-exclusion chromatography, PF4 tetramerization mutagenesis, platelet activation and antibody-binding assays; plus identification of USF1/USF2 transcriptional control","pmids":["15304392","15187018"],"confidence":"High","gaps":["Structural model of ultralarge complex not resolved","Determinants of the conformational neoepitope not fully mapped"]},{"year":2005,"claim":"Established that PF4/heparin complexes are T cell-dependent antigens and revealed receptor-specific opposing effects on T helper differentiation via CXCR3 isoforms.","evidence":"Euthymic vs athymic mouse immunization; T-cell line cytokine, promoter, and CXCR3-blocking assays","pmids":["15845897","16337473"],"confidence":"Medium","gaps":["CXCR3-A vs CXCR3-B signaling divergence shown in single laboratory","In vivo relevance of TH2 skewing not established"]},{"year":2007,"claim":"Distinguished regulated, PKC-dependent secretion of CXCL4 from constitutive secretion of its variant CXCL4L1, defining how PF4 release is controlled.","evidence":"Transfection of multiple cell types, subcellular fractionation, PKC stimulation and secretion assays","pmids":["17218382"],"confidence":"High","gaps":["Granule sorting determinants not identified"]},{"year":2010,"claim":"Connected PF4 to organ fibrosis and dissected myeloid signaling, showing genetic deletion reduces liver fibrosis and that PF4 modulates monocyte chemokine receptors and survival pathways.","evidence":"Cxcl4−/− mice in two liver injury models; monocyte CCR downregulation via autocrine TNF-α; SphK1 enzyme/translocation/siRNA studies; CXCR3-dependent microglial migration","pmids":["20162727","21088050","20104488","18248618"],"confidence":"Medium","gaps":["Direct fibroblast receptor for PF4 not identified at this stage","SphK1 and TNF-α pathways each from single laboratory"]},{"year":2011,"claim":"Identified RUNX1 as a direct transcriptional driver of PF4 in megakaryocytes and outlined the dual CXCR3-B/proteoglycan signaling architecture.","evidence":"ChIP, EMSA, reporter mutagenesis, RUNX1 knockdown/overexpression; synthesis of CXCR3-B (Gs/cAMP/p38) and proteoglycan (Src/Syk/Rac2/SphK1) signaling","pmids":["21129147","21295372"],"confidence":"High","gaps":["Signaling synthesis aggregates components from disparate single studies","Interplay between transcriptional regulators not fully mapped"]},{"year":2012,"claim":"Provided a mechanism for HIT thrombosis by showing antibody complexes drive monocyte tissue factor expression through FcγRI and MEK1-ERK1/2.","evidence":"Ex vivo monocyte stimulation with KKO and patient plasma, TF and microparticle assays, FcγRI blocking, MEK inhibition","pmids":["22394597"],"confidence":"High","gaps":["Relative contributions of monocyte vs platelet procoagulant activity in vivo not quantified"]},{"year":2014,"claim":"Identified megakaryocyte-derived CXCL4 as a niche signal enforcing HSC quiescence, linking platelet biology to stem cell regulation.","evidence":"In vivo CXCL4 injection, Cxcl4−/− mice, MK depletion, 3D whole-mount imaging; plus CXCR3/p38-p53-Bax apoptotic cascade in intestinal epithelium","pmids":["25326802","24800927"],"confidence":"High","gaps":["HSC receptor for CXCL4 quiescence signal not defined","Reconciliation of quiescence-promoting vs self-renewal roles incomplete"]},{"year":2016,"claim":"Demonstrated an autocrine/paracrine requirement for CXCL4 in HSPC survival and self-renewal, complementing the niche quiescence role.","evidence":"siRNA knockdown in human CD34+ cells, Cxcl4−/− mice, serial transplantation, colony assays","pmids":["27222476"],"confidence":"High","gaps":["CXCR2 mechanistic role in HSPCs not fully resolved"]},{"year":2018,"claim":"Expanded the PF4 receptor repertoire and innate-immune amplifying functions: CCR1 agonism for monocyte chemotaxis and TLR8 synergy driving inflammasome and enhancer remodeling.","evidence":"Chemotaxis/calcium/PTX/chondroitinase/CCR1-transfectant assays; kinase, IRF5, NLRP3, and ATAC/ChIP epigenomic profiling; CD4 T-cell/CD40 dependence of antibody production","pmids":["29930254","35701499","25595736"],"confidence":"High","gaps":["How GAG presentation couples to CCR1 activation not structurally defined","Endogenous TLR8 ligand context in vivo not established"]},{"year":2019,"claim":"Defined PF4 as a nucleic-acid-organizing scaffold that amplifies TLR9 responses, and mapped its heterodimerization with CXCL12 controlling cancer cell migration.","evidence":"Biophysical liquid-crystalline complex assays, pDC stimulation, CXCR3-independence; NMR interface mapping with CXCL12 and migration assays; CD36-dependent macrophage phagocytosis post-MI","pmids":["31043596","31785332","30169632"],"confidence":"High","gaps":["Receptor sensing the liquid-crystalline complex beyond endosomal TLR9 not defined","CD36 mechanism shown in single laboratory"]},{"year":2022,"claim":"Established PF4 as a direct pro-fibrotic effector across multiple organs and dissected the monocyte-PDGF-BB and CIITA/DC reprogramming routes to fibrosis.","evidence":"Cxcl4−/− and human CXCL4 overexpression mice in multiple fibrotic models, blocking, in vitro myofibroblast differentiation; PDGF-BB and CIITA pathway dissection","pmids":["34986347","32284212","33042127"],"confidence":"High","gaps":["Direct fibroblast/endothelial receptor mediating myofibroblast differentiation not identified","PDGF-BB and CIITA routes each from single laboratory"]},{"year":2023,"claim":"Resolved how endothelial GAG sulfation tunes PF4-driven, receptor-independent leukocyte recruitment, extended nucleic-acid sensing to RNA, and revealed a beneficial neurogenic exerkine role.","evidence":"Biophysical GAG-binding/mutant studies with leukocyte adhesion and permeability assays; CXCL4-RNA RNase protection and TLR7/8-dependent DC stimulation; platelet depletion and CXCL4 injection in aged mice","pmids":["36640356","36614095","37587147"],"confidence":"Medium","gaps":["Receptor for hippocampal neurogenic effect not identified","RNA-complex mechanism from single laboratory"]},{"year":2024,"claim":"Identified c-Mpl/JAK2 as a direct PF4 platelet-activating receptor axis, unifying VITT and HIT platelet activation through dual FcγRIIA and c-Mpl engagement.","evidence":"PF4-c-Mpl binding, JAK2/STAT3/STAT5 phosphorylation, pathway inhibition, platelet aggregation with VITT sera and patient IgG","pmids":["37883794"],"confidence":"High","gaps":["Structural basis of PF4 binding to c-Mpl not resolved","Relative contribution of c-Mpl vs FcγRIIA in vivo not quantified"]},{"year":null,"claim":"The direct cell-surface receptor(s) mediating PF4-induced myofibroblast differentiation, HSC quiescence, and neuro-regenerative effects remain unidentified, and a unified structural model linking polyanion-complex assembly to the distinct receptor systems is lacking.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No defined receptor for the direct pro-fibrotic effect","No structural model connecting tetramer/complex states to integrin, CXCR3, CCR1, c-Mpl, and CD36 engagement","Endogenous physiological versus pathological balance of PF4 functions undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[8,9,24]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[0,6,32,37]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[18,37]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[8,24]}],"localization":[{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[3]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[3,22]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[22]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,12,23,28]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[0,24,37]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,9,17,24]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,24,29,30]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[4,5]}],"complexes":[],"partners":["CXCR3","CCR1","MPL","CXCL12","ITGAV","ITGB3","CD36","FCGR2A"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P02776","full_name":"Platelet factor 4","aliases":["C-X-C motif chemokine 4","Iroplact","Oncostatin-A"],"length_aa":101,"mass_kda":10.8,"function":"Chemokine released during platelet aggregation that plays a role in different biological processes including hematopoiesis, cell proliferation, differentiation, and activation (PubMed:29930254, PubMed:9531587). Acts via different functional receptors including CCR1, CXCR3A or CXCR3B (PubMed:18174362, PubMed:29930254). Upon interaction with CXCR3A receptor, induces activated T-lymphocytes migration mediated via downstream Ras/extracellular signal-regulated kinase (ERK) signaling (PubMed:18174362, PubMed:24469069). Neutralizes the anticoagulant effect of heparin by binding more strongly to heparin than to the chondroitin-4-sulfate chains of the carrier molecule. Plays a role in the inhibition of hematopoiesis and in the maintenance of hematopoietic stem cell (HSC) quiescence (PubMed:9531587). Chemotactic for neutrophils and monocytes via CCR1 (PubMed:29930254). Inhibits endothelial cell proliferation. In cooperation with toll-like receptor 8/TLR8, induces chromatin remodeling and activates inflammatory gene expression via the TBK1-IRF5 axis (PubMed:35701499). In addition, induces myofibroblast differentiation and collagen synthesis in different precursor cells, including endothelial cells, by stimulating endothelial-to-mesenchymal transition (PubMed:34986347). Interacts with thrombomodulin/THBD to enhance the activation of protein C and thus potentiates its anticoagulant activity (PubMed:9395524)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P02776/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PF4","classification":"Not Classified","n_dependent_lines":58,"n_total_lines":1090,"dependency_fraction":0.05321100917431193},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PF4","total_profiled":1310},"omim":[{"mim_id":"604852","title":"CHEMOKINE, CXC MOTIF, LIGAND 11; CXCL11","url":"https://www.omim.org/entry/604852"},{"mim_id":"603413","title":"TIA1 CYTOTOXIC GRANULE-ASSOCIATED RNA-BINDING PROTEIN-LIKE 1; TIAL1","url":"https://www.omim.org/entry/603413"},{"mim_id":"601704","title":"CHEMOKINE, CXC MOTIF, LIGAND 9; CXCL9","url":"https://www.omim.org/entry/601704"},{"mim_id":"600324","title":"CHEMOKINE, CXC MOTIF, LIGAND 5; CXCL5","url":"https://www.omim.org/entry/600324"},{"mim_id":"300574","title":"CHEMOKINE, CXC MOTIF, RECEPTOR 3; CXCR3","url":"https://www.omim.org/entry/300574"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"bone marrow","ntpm":28.0},{"tissue":"lymphoid tissue","ntpm":9.8}],"url":"https://www.proteinatlas.org/search/PF4"},"hgnc":{"alias_symbol":["SCYB4","CXCL4"],"prev_symbol":[]},"alphafold":{"accession":"P02776","domains":[{"cath_id":"2.40.50.40","chopping":"51-99","consensus_level":"high","plddt":89.6178,"start":51,"end":99}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02776","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02776-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02776-F1-predicted_aligned_error_v6.png","plddt_mean":75.06},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PF4","jax_strain_url":"https://www.jax.org/strain/search?query=PF4"},"sequence":{"accession":"P02776","fasta_url":"https://rest.uniprot.org/uniprotkb/P02776.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02776/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02776"}},"corpus_meta":[{"pmid":"11023497","id":"PMC_11023497","title":"Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11023497","citation_count":546,"is_preprint":false},{"pmid":"25326802","id":"PMC_25326802","title":"Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion.","date":"2014","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25326802","citation_count":484,"is_preprint":false},{"pmid":"24350901","id":"PMC_24350901","title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis.","date":"2013","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24350901","citation_count":369,"is_preprint":false},{"pmid":"18489711","id":"PMC_18489711","title":"Quantitative interpretation of optical density measurements using PF4-dependent enzyme-immunoassays.","date":"2008","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/18489711","citation_count":266,"is_preprint":false},{"pmid":"22275902","id":"PMC_22275902","title":"Macrophage Phenotype Modulation by CXCL4 in Atherosclerosis.","date":"2012","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/22275902","citation_count":242,"is_preprint":false},{"pmid":"36807143","id":"PMC_36807143","title":"Platelet-instructed SPP1+ macrophages drive myofibroblast activation in fibrosis in a CXCL4-dependent manner.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36807143","citation_count":231,"is_preprint":false},{"pmid":"15304392","id":"PMC_15304392","title":"Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15304392","citation_count":223,"is_preprint":false},{"pmid":"22402885","id":"PMC_22402885","title":"VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients.","date":"2012","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/22402885","citation_count":186,"is_preprint":false},{"pmid":"8616093","id":"PMC_8616093","title":"Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia.","date":"1996","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/8616093","citation_count":168,"is_preprint":false},{"pmid":"20004006","id":"PMC_20004006","title":"Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis.","date":"2009","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/20004006","citation_count":147,"is_preprint":false},{"pmid":"19910578","id":"PMC_19910578","title":"CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages.","date":"2009","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/19910578","citation_count":140,"is_preprint":false},{"pmid":"2523411","id":"PMC_2523411","title":"Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide.","date":"1989","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/2523411","citation_count":140,"is_preprint":false},{"pmid":"20162727","id":"PMC_20162727","title":"CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis.","date":"2010","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/20162727","citation_count":136,"is_preprint":false},{"pmid":"31043596","id":"PMC_31043596","title":"CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31043596","citation_count":122,"is_preprint":false},{"pmid":"33988688","id":"PMC_33988688","title":"Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/33988688","citation_count":122,"is_preprint":false},{"pmid":"25858640","id":"PMC_25858640","title":"Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis.","date":"2015","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/25858640","citation_count":108,"is_preprint":false},{"pmid":"37587147","id":"PMC_37587147","title":"Platelet-derived exerkine CXCL4/platelet factor 4 rejuvenates hippocampal neurogenesis and restores cognitive function in aged mice.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37587147","citation_count":103,"is_preprint":false},{"pmid":"16337473","id":"PMC_16337473","title":"CXCR3-mediated opposite effects of CXCL10 and CXCL4 on TH1 or TH2 cytokine production.","date":"2005","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16337473","citation_count":91,"is_preprint":false},{"pmid":"24663337","id":"PMC_24663337","title":"CXCL4-induced plaque macrophages can be specifically identified by co-expression of MMP7+S100A8+ in vitro and in vivo.","date":"2014","source":"Innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/24663337","citation_count":91,"is_preprint":false},{"pmid":"22394597","id":"PMC_22394597","title":"PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22394597","citation_count":89,"is_preprint":false},{"pmid":"28899579","id":"PMC_28899579","title":"CXCL4-induced macrophages in human atherosclerosis.","date":"2017","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/28899579","citation_count":86,"is_preprint":false},{"pmid":"32726410","id":"PMC_32726410","title":"Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN.","date":"2020","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32726410","citation_count":86,"is_preprint":false},{"pmid":"21508508","id":"PMC_21508508","title":"CXCL4 and CXCL10 predict risk of fatal cerebral malaria.","date":"2011","source":"Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/21508508","citation_count":85,"is_preprint":false},{"pmid":"18539895","id":"PMC_18539895","title":"Immune complexes formed following the binding of anti-platelet factor 4 (CXCL4) antibodies to CXCL4 stimulate human neutrophil activation and cell adhesion.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18539895","citation_count":75,"is_preprint":false},{"pmid":"29930254","id":"PMC_29930254","title":"CXCL4/Platelet Factor 4 is an agonist of CCR1 and drives human monocyte migration.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29930254","citation_count":74,"is_preprint":false},{"pmid":"23352833","id":"PMC_23352833","title":"Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy.","date":"2013","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/23352833","citation_count":73,"is_preprint":false},{"pmid":"20806113","id":"PMC_20806113","title":"Interaction of PF4 (CXCL4) with the vasculature: a role in atherosclerosis and angiogenesis.","date":"2010","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/20806113","citation_count":70,"is_preprint":false},{"pmid":"18248618","id":"PMC_18248618","title":"Expression of CXCL4 in microglia in vitro and in vivo and its possible signaling through CXCR3.","date":"2008","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18248618","citation_count":70,"is_preprint":false},{"pmid":"34986347","id":"PMC_34986347","title":"CXCL4 drives fibrosis by promoting several key cellular and molecular processes.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34986347","citation_count":65,"is_preprint":false},{"pmid":"23300543","id":"PMC_23300543","title":"Lineage tracing of Pf4-Cre marks hematopoietic stem cells and their progeny.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23300543","citation_count":64,"is_preprint":false},{"pmid":"27222476","id":"PMC_27222476","title":"CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/27222476","citation_count":61,"is_preprint":false},{"pmid":"37883798","id":"PMC_37883798","title":"Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure.","date":"2023","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/37883798","citation_count":59,"is_preprint":false},{"pmid":"33420306","id":"PMC_33420306","title":"Platelet CXCL4 mediates neutrophil extracellular traps formation in ANCA-associated vasculitis.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33420306","citation_count":57,"is_preprint":false},{"pmid":"21295372","id":"PMC_21295372","title":"Molecular pathways of platelet factor 4/CXCL4 signaling.","date":"2011","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21295372","citation_count":56,"is_preprint":false},{"pmid":"35512902","id":"PMC_35512902","title":"Platelet-activating anti-PF4 disorders: An overview.","date":"2022","source":"Seminars in hematology","url":"https://pubmed.ncbi.nlm.nih.gov/35512902","citation_count":55,"is_preprint":false},{"pmid":"17218382","id":"PMC_17218382","title":"PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17218382","citation_count":55,"is_preprint":false},{"pmid":"30169632","id":"PMC_30169632","title":"Exogenous CXCL4 infusion inhibits macrophage phagocytosis by limiting CD36 signalling to enhance post-myocardial infarction cardiac dilation and mortality.","date":"2019","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/30169632","citation_count":52,"is_preprint":false},{"pmid":"33795809","id":"PMC_33795809","title":"CD8+ T cells inhibit metastasis and CXCL4 regulates its function.","date":"2021","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33795809","citation_count":51,"is_preprint":false},{"pmid":"29325582","id":"PMC_29325582","title":"Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis.","date":"2018","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29325582","citation_count":51,"is_preprint":false},{"pmid":"21848694","id":"PMC_21848694","title":"The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies.","date":"2011","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/21848694","citation_count":48,"is_preprint":false},{"pmid":"34099640","id":"PMC_34099640","title":"The C5a/C5a receptor 1 axis controls tissue neovascularization through CXCL4 release from platelets.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34099640","citation_count":47,"is_preprint":false},{"pmid":"36640356","id":"PMC_36640356","title":"Chemokine CXCL4 interactions with extracellular matrix proteoglycans mediate widespread immune cell recruitment independent of chemokine receptors.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36640356","citation_count":47,"is_preprint":false},{"pmid":"23337289","id":"PMC_23337289","title":"Platelet factor-4 (CXCL4/PF-4): an angiostatic chemokine for cancer therapy.","date":"2013","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/23337289","citation_count":46,"is_preprint":false},{"pmid":"30481563","id":"PMC_30481563","title":"Non-platelet-derived CXCL4 differentially regulates cytotoxic and regulatory T cells through CXCR3 to suppress the immune response to colon cancer.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/30481563","citation_count":45,"is_preprint":false},{"pmid":"32898858","id":"PMC_32898858","title":"A prospective, blinded study of a PF4-dependent assay for HIT diagnosis.","date":"2021","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/32898858","citation_count":42,"is_preprint":false},{"pmid":"32707718","id":"PMC_32707718","title":"Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32707718","citation_count":42,"is_preprint":false},{"pmid":"35113987","id":"PMC_35113987","title":"Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/35113987","citation_count":41,"is_preprint":false},{"pmid":"33042127","id":"PMC_33042127","title":"CXCL4 Links Inflammation and Fibrosis by Reprogramming Monocyte-Derived Dendritic Cells in vitro.","date":"2020","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33042127","citation_count":40,"is_preprint":false},{"pmid":"26478565","id":"PMC_26478565","title":"Platelet secretion of CXCL4 is Rac1-dependent and regulates neutrophil infiltration and tissue damage in septic lung damage.","date":"2015","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26478565","citation_count":40,"is_preprint":false},{"pmid":"21129147","id":"PMC_21129147","title":"Mechanism of platelet factor 4 (PF4) deficiency with RUNX1 haplodeficiency: RUNX1 is a transcriptional regulator of PF4.","date":"2011","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/21129147","citation_count":40,"is_preprint":false},{"pmid":"19625657","id":"PMC_19625657","title":"The cathelicidin LL-37 activates human mast cells and is degraded by mast cell tryptase: counter-regulation by CXCL4.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19625657","citation_count":40,"is_preprint":false},{"pmid":"32246813","id":"PMC_32246813","title":"Prophage encoding toxin/antitoxin system PfiT/PfiA inhibits Pf4 production in Pseudomonas aeruginosa.","date":"2020","source":"Microbial biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/32246813","citation_count":39,"is_preprint":false},{"pmid":"18648521","id":"PMC_18648521","title":"The CXC-chemokine CXCL4 interacts with integrins implicated in angiogenesis.","date":"2008","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/18648521","citation_count":38,"is_preprint":false},{"pmid":"28515281","id":"PMC_28515281","title":"CXCL4 Exposure Potentiates TLR-Driven Polarization of Human Monocyte-Derived Dendritic Cells and Increases Stimulation of T Cells.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28515281","citation_count":38,"is_preprint":false},{"pmid":"24800927","id":"PMC_24800927","title":"Activation of p38-MAPK by CXCL4/CXCR3 axis contributes to p53-dependent intestinal apoptosis initiated by 5-fluorouracil.","date":"2014","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24800927","citation_count":37,"is_preprint":false},{"pmid":"27633389","id":"PMC_27633389","title":"MKEY, a Peptide Inhibitor of CXCL4-CCL5 Heterodimer Formation, Protects Against Stroke in Mice.","date":"2016","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/27633389","citation_count":37,"is_preprint":false},{"pmid":"30309891","id":"PMC_30309891","title":"Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/30309891","citation_count":37,"is_preprint":false},{"pmid":"30055136","id":"PMC_30055136","title":"Surgical trauma contributes to progression of colon cancer by downregulating CXCL4 and recruiting MDSCs.","date":"2018","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/30055136","citation_count":37,"is_preprint":false},{"pmid":"35701499","id":"PMC_35701499","title":"CXCL4 synergizes with TLR8 for TBK1-IRF5 activation, epigenomic remodeling and inflammatory response in human monocytes.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35701499","citation_count":36,"is_preprint":false},{"pmid":"37883794","id":"PMC_37883794","title":"PF4 activates the c-Mpl-Jak2 pathway in platelets.","date":"2024","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/37883794","citation_count":36,"is_preprint":false},{"pmid":"19249435","id":"PMC_19249435","title":"Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up.","date":"2009","source":"American heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/19249435","citation_count":36,"is_preprint":false},{"pmid":"803847","id":"PMC_803847","title":"Antigenic and antiheparin properties of human platelet factor 4 (PF4).","date":"1975","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/803847","citation_count":36,"is_preprint":false},{"pmid":"10319581","id":"PMC_10319581","title":"Significantly elevated expression of PF4 (platelet factor 4) and eotaxin in the NOA mouse, a model for atopic dermatitis.","date":"1999","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10319581","citation_count":36,"is_preprint":false},{"pmid":"32284212","id":"PMC_32284212","title":"CXCL4 triggers monocytes and macrophages to produce PDGF-BB, culminating in fibroblast activation: Implications for systemic sclerosis.","date":"2020","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/32284212","citation_count":33,"is_preprint":false},{"pmid":"27183218","id":"PMC_27183218","title":"Platelet-derived CXCL4 regulates neutrophil infiltration and tissue damage in severe acute pancreatitis.","date":"2016","source":"Translational research : the journal of laboratory and clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/27183218","citation_count":33,"is_preprint":false},{"pmid":"28467728","id":"PMC_28467728","title":"The PF4/PPBP/CXCL5 Gene Cluster Is Associated with Periodontitis.","date":"2017","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/28467728","citation_count":33,"is_preprint":false},{"pmid":"27634764","id":"PMC_27634764","title":"Dual Roles for CXCL4 Chemokines and CXCR3 in Angiogenesis and Invasion of Pancreatic Cancer.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27634764","citation_count":32,"is_preprint":false},{"pmid":"33050376","id":"PMC_33050376","title":"Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19.","date":"2020","source":"Antibodies (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33050376","citation_count":31,"is_preprint":false},{"pmid":"15845897","id":"PMC_15845897","title":"PF4/heparin complexes are T cell-dependent antigens.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15845897","citation_count":31,"is_preprint":false},{"pmid":"30917957","id":"PMC_30917957","title":"Cleavage of anti-PF4/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia.","date":"2019","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/30917957","citation_count":31,"is_preprint":false},{"pmid":"26467272","id":"PMC_26467272","title":"Further insights into the anti-PF4/heparin IgM immune response.","date":"2015","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/26467272","citation_count":31,"is_preprint":false},{"pmid":"39152118","id":"PMC_39152118","title":"ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39152118","citation_count":30,"is_preprint":false},{"pmid":"27828999","id":"PMC_27828999","title":"CXCL4 and CXCL4L1 Differentially Affect Monocyte Survival and Dendritic Cell Differentiation and Phagocytosis.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27828999","citation_count":30,"is_preprint":false},{"pmid":"25520708","id":"PMC_25520708","title":"Environmental cues and genes involved in establishment of the superinfective Pf4 phage of Pseudomonas aeruginosa.","date":"2014","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/25520708","citation_count":29,"is_preprint":false},{"pmid":"37182698","id":"PMC_37182698","title":"Investigation of anti-PF4 versus anti-PF4/heparin reactivity using fluid-phase enzyme immunoassay for 4 anti-PF4 disorders: classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, vaccine-induced immune thrombotic thrombocytopenia, and spontaneous HIT.","date":"2023","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/37182698","citation_count":28,"is_preprint":false},{"pmid":"35263420","id":"PMC_35263420","title":"Natural history of PF4 antibodies in vaccine-induced immune thrombocytopenia and thrombosis.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/35263420","citation_count":28,"is_preprint":false},{"pmid":"22555803","id":"PMC_22555803","title":"Impaired CXCL4 expression in tumor-associated macrophages (TAMs) of ovarian cancers arising in endometriosis.","date":"2012","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/22555803","citation_count":28,"is_preprint":false},{"pmid":"25595736","id":"PMC_25595736","title":"Critical role of CD4 T cells in PF4/heparin antibody production in mice.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/25595736","citation_count":26,"is_preprint":false},{"pmid":"35720325","id":"PMC_35720325","title":"Urine ALCAM, PF4 and VCAM-1 Surpass Conventional Metrics in Identifying Nephritis Disease Activity in Childhood-Onset Systemic Lupus Erythematosus.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35720325","citation_count":25,"is_preprint":false},{"pmid":"21088050","id":"PMC_21088050","title":"CXC chemokine ligand 4 (CXCL4) down-regulates CC chemokine receptor expression on human monocytes.","date":"2010","source":"Innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/21088050","citation_count":25,"is_preprint":false},{"pmid":"26479470","id":"PMC_26479470","title":"CXCL4 mediates tumor regrowth after chemotherapy by suppression of antitumor immunity.","date":"2015","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26479470","citation_count":25,"is_preprint":false},{"pmid":"25373734","id":"PMC_25373734","title":"Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47-70) and CXCL4L1(47-70) in an EGF-dependent breast cancer model.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25373734","citation_count":25,"is_preprint":false},{"pmid":"19773294","id":"PMC_19773294","title":"Platelet factor 4 (CXCL4) facilitates human macrophage infection with HIV-1 and potentiates virus replication.","date":"2009","source":"Innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/19773294","citation_count":23,"is_preprint":false},{"pmid":"30273811","id":"PMC_30273811","title":"Anti-PF4/heparin antibodies are increased in hospitalized patients with bacterial sepsis.","date":"2018","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/30273811","citation_count":23,"is_preprint":false},{"pmid":"31785332","id":"PMC_31785332","title":"CXCL12-CXCL4 heterodimerization prevents CXCL12-driven breast cancer cell migration.","date":"2019","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/31785332","citation_count":22,"is_preprint":false},{"pmid":"36036571","id":"PMC_36036571","title":"Pf4 Phage Variant Infection Reduces Virulence-Associated Traits in Pseudomonas aeruginosa.","date":"2022","source":"Microbiology spectrum","url":"https://pubmed.ncbi.nlm.nih.gov/36036571","citation_count":22,"is_preprint":false},{"pmid":"24469069","id":"PMC_24469069","title":"CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase.","date":"2014","source":"Angiogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24469069","citation_count":22,"is_preprint":false},{"pmid":"38307410","id":"PMC_38307410","title":"Hyperactivation of β-catenin signal in hepatocellular carcinoma recruits myeloid-derived suppressor cells through PF4-CXCR3 axis.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38307410","citation_count":21,"is_preprint":false},{"pmid":"34559222","id":"PMC_34559222","title":"Hypoxia and TLR9 activation drive CXCL4 production in systemic sclerosis plasmacytoid dendritic cells via mtROS and HIF-2α.","date":"2022","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34559222","citation_count":21,"is_preprint":false},{"pmid":"36006172","id":"PMC_36006172","title":"Quantitative interpretation of PF4/heparin-EIA optical densities in predicting platelet-activating VITT antibodies.","date":"2022","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/36006172","citation_count":21,"is_preprint":false},{"pmid":"15187018","id":"PMC_15187018","title":"Upstream stimulatory factors stimulate transcription through E-box motifs in the PF4 gene in megakaryocytes.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15187018","citation_count":20,"is_preprint":false},{"pmid":"36614095","id":"PMC_36614095","title":"CXCL4-RNA Complexes Circulate in Systemic Sclerosis and Amplify Inflammatory/Pro-Fibrotic Responses by Myeloid Dendritic Cells.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36614095","citation_count":19,"is_preprint":false},{"pmid":"35746731","id":"PMC_35746731","title":"Filamentous Pseudomonas Phage Pf4 in the Context of Therapy-Inducibility, Infectivity, Lysogenic Conversion, and Potential Application.","date":"2022","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/35746731","citation_count":19,"is_preprint":false},{"pmid":"30573633","id":"PMC_30573633","title":"Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT.","date":"2018","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/30573633","citation_count":19,"is_preprint":false},{"pmid":"20104488","id":"PMC_20104488","title":"CXCL4-induced monocyte survival, cytokine expression, and oxygen radical formation is regulated by sphingosine kinase 1.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20104488","citation_count":18,"is_preprint":false},{"pmid":"35638845","id":"PMC_35638845","title":"The c-di-GMP Phosphodiesterase PipA (PA0285) Regulates Autoaggregation and Pf4 Bacteriophage Production in Pseudomonas aeruginosa PAO1.","date":"2022","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/35638845","citation_count":18,"is_preprint":false},{"pmid":"36926331","id":"PMC_36926331","title":"New perspectives on the induction and acceleration of immune-associated thrombosis by PF4 and VWF.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36926331","citation_count":17,"is_preprint":false},{"pmid":"26803701","id":"PMC_26803701","title":"Regulatory role of Megakaryocytes on Hematopoietic Stem Cells Quiescence by CXCL4/PF4 in Bone Marrow Niche.","date":"2016","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/26803701","citation_count":17,"is_preprint":false},{"pmid":"35054772","id":"PMC_35054772","title":"Differential Effects of Platelet Factor 4 (CXCL4) and Its Non-Allelic Variant (CXCL4L1) on Cultured Human Vascular Smooth Muscle Cells.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35054772","citation_count":17,"is_preprint":false},{"pmid":"36325331","id":"PMC_36325331","title":"High levels of PF4, VEGF-A, and classical monocytes correlate with the platelets count and inflammation during active tuberculosis.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36325331","citation_count":17,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":58011,"output_tokens":10817,"usd":0.168144,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21343,"output_tokens":5751,"usd":0.125245,"stage2_stop_reason":"end_turn"},"total_usd":0.293389,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"PF4 tetramers and unfractionated heparin form ultralarge complexes (>670 kDa) over a narrow molar ratio (~1:1 PF4:heparin); these ultralarge complexes are more reactive toward HIT-like monoclonal antibodies and promote greater FcγRIIA-dependent platelet activation than smaller complexes. Formation of ultralarge complexes required intact PF4 tetramers (demonstrated by mutation studies) and did not occur with low-molecular-weight heparin or fondaparinux.\",\n      \"method\": \"Electron microscopy, size-exclusion chromatography, mutagenesis of PF4 tetramerization, platelet activation assays, antibody-binding assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with defined components, electron microscopy, mutagenesis, multiple orthogonal functional assays in single rigorous study\",\n      \"pmids\": [\"15304392\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Neutrophil gelatinase B (MMP-9) degrades PF4 (platelet factor 4), in contrast to its potentiating effect on IL-8; PF4 is thus a substrate of MMP-9 proteolysis.\",\n      \"method\": \"In vitro proteolysis assay with purified human neutrophil progelatinase B activated by stromelysin-1; gel analysis of cleavage products\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro enzyme assay with purified components; rigorous controls comparing multiple chemokines\",\n      \"pmids\": [\"11023497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Megakaryocytes are the predominant source of CXCL4 in the bone marrow niche; CXCL4 secreted by megakaryocytes directly regulates HSC quiescence. In vivo CXCL4 injection increased HSC quiescence and reduced HSC number, while Cxcl4−/− mice showed increased HSC number and proliferation. 3D whole-mount imaging confirmed HSCs are preferentially located adjacent to megakaryocytes.\",\n      \"method\": \"In vivo CXCL4 injection, Cxcl4−/− mouse model, selective MK depletion, 3D whole-mount imaging, gene expression analysis, flow cytometry\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO, in vivo gain-of-function, direct imaging, multiple orthogonal methods; replicated across complementary approaches\",\n      \"pmids\": [\"25326802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CXCL4 is stored in secretory granules and released in response to protein kinase C (PKC) activation, whereas its non-allelic variant CXCL4L1 is continuously secreted via a constitutive pathway. This difference in subcellular localization and regulated secretion was established in multiple transfected cell types and confirmed in lymphocytes (primarily CXCL4) and smooth muscle cells (primarily CXCL4L1).\",\n      \"method\": \"Transfection of multiple cell types, subcellular fractionation/localization, PKC stimulation assays, secretion pathway analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple cell types, orthogonal localization and secretion assays, comparison with variant chemokine as internal control\",\n      \"pmids\": [\"17218382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"RUNX1 is a direct transcriptional regulator of the PF4 gene. RUNX1 binds to consensus sites at −1774/−1769 and −157/−152 on the PF4 promoter. Mutation of either site markedly reduced promoter activity; RUNX1 knockdown decreased and RUNX1 overexpression increased PF4 promoter activity and protein levels.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), electrophoretic mobility shift assay (EMSA), luciferase reporter assay, siRNA knockdown, RUNX1 overexpression in HEL cells\",\n      \"journal\": \"Journal of thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP, EMSA, reporter mutagenesis, gain- and loss-of-function in single study\",\n      \"pmids\": [\"21129147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Upstream stimulatory factors USF1 and USF2 bind E-box motifs in the TME regulatory element of the PF4 promoter and strongly transactivate PF4 expression in megakaryocytic cells; physiological binding of USF1/2 to the TME in rat megakaryocytes was confirmed.\",\n      \"method\": \"Mass spectrometry identification of promoter-binding proteins, ChIP assay in primary megakaryocytes, luciferase reporter assay, EMSA, RT-PCR\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — ChIP in primary cells, EMSA, reporter assays with defined binding sites, protein identification by MS\",\n      \"pmids\": [\"15187018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCL4 organizes self-DNA and microbial DNA into liquid crystalline immune complexes that amplify TLR9-mediated plasmacytoid dendritic cell hyperactivation and interferon-α production. This activity does not require CXCR3. CXCL4-DNA complexes were detected in vivo in SSc blood and correlated with the type I IFN signature.\",\n      \"method\": \"Biophysical characterization (liquid crystalline complex formation), in vitro pDC stimulation assays, CXCR3 blocking/knockout experiments, detection of complexes in patient plasma, skin pDC immunostaining\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — biophysical reconstitution, multiple cell-based assays, receptor-independence demonstrated by blocking and KO, in vivo patient samples\",\n      \"pmids\": [\"31043596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCL4 directly downregulates CD163 (hemoglobin-haptoglobin scavenger receptor) expression on human macrophages differentiated from monocytes, resulting in inability to upregulate heme oxygenase-1 in response to hemoglobin-haptoglobin complexes. CXCL4's effect was neutralized by heparin (which binds CXCL4) and blocked by chlorate pretreatment (inhibiting glycosaminoglycan synthesis), indicating CXCL4 acts through cell-surface glycosaminoglycans.\",\n      \"method\": \"Flow cytometry, mRNA quantification (time-course), heparin neutralization, chlorate inhibition of GAG synthesis, platelet releasate experiments, immunofluorescence of human plaques\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods, mechanism-of-action dissected by receptor/GAG blockade, in vivo correlation in human tissue\",\n      \"pmids\": [\"19910578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CXCL4 is an agonist of CCR1 and drives chemotaxis of primary human monocytes through CCR1. CXCL4-induced migration and calcium responses in THP-1 cells were pertussis toxin-sensitive (implying Gi-coupled GPCR), abrogated by chondroitinase ABC (requiring cell-surface GAG presentation), insensitive to CXCR3 antagonist, and inhibited by a CCR1 antagonist. CXCL4 also induced CCR1 endocytosis.\",\n      \"method\": \"Chemotaxis assays, intracellular calcium measurements, pertussis toxin treatment, chondroitinase ABC treatment, CCR1-transfectant migration assays, CCR1 endocytosis assay, CCR1 antagonist inhibition\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods, receptor identified by transfectant assays, confirmed in primary human monocytes with pharmacological inhibition\",\n      \"pmids\": [\"29930254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CXCL4 and CXCL10 exert opposite effects on human TH1/TH2 cytokine production via their respective interactions with CXCR3-B and CXCR3-A. CXCL4 downregulates IFN-γ and upregulates TH2 cytokines (IL-4, IL-5, IL-13), downregulates T-bet, upregulates GATA-3, and induces direct activation of IL-5 and IL-13 promoters. These effects were blocked by anti-CXCR3 antibody.\",\n      \"method\": \"Quantitative RT-PCR, flow cytometry, ELISA on antigen-specific and polyclonally activated T-cell lines, anti-CXCR3 blocking antibody, IL-5/IL-13 promoter activation assays\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (qPCR, ELISA, promoter assays, blocking Ab), single laboratory\",\n      \"pmids\": [\"16337473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CXCL4 interacts with αvβ3, αvβ5, and α5β1 integrins on human endothelial cells. Immobilized CXCL4 supports endothelial cell adhesion, spreading, and migration in an integrin-dependent manner, whereas soluble CXCL4 inhibits integrin-dependent adhesion and migration, contributing to its anti-angiogenic effect.\",\n      \"method\": \"Cell adhesion assays with integrin-transfected CHO cells, HUVEC adhesion/spreading/migration assays, integrin-blocking antibodies\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cell assays with blocking antibodies, multiple integrin receptors tested, single laboratory\",\n      \"pmids\": [\"18648521\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"CXCL4 binds to chondroitin sulfate proteoglycans on neutrophil surfaces; immune complexes of PF4 and anti-PF4 antibodies colocalize with CD32a (FcγRIIA) on neutrophils and activate neutrophils (~3-fold increase in Mac-1 expression, degranulation, enhanced adhesion). Chondroitinase ABC treatment blocked PF4 binding and cell activation. Arginine 49 of PF4 was identified as important for stabilizing PF4-chondroitin binding.\",\n      \"method\": \"Flow cytometry, confocal microscopy, chondroitinase ABC treatment, anti-CD32/FcγRII blocking antibody, recombinant PF4 mutagenesis (Arg49), degranulation assays, cell adhesion assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — site-directed mutagenesis identifying key residue, multiple orthogonal functional assays, receptor colocalization by confocal microscopy\",\n      \"pmids\": [\"18539895\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PF4/heparin antibody complexes induce monocyte tissue factor (TF) expression and release of TF-positive microparticles via engagement of FcγRI receptor and activation of the MEK1-ERK1/2 signaling pathway, providing a mechanism for thrombosis in HIT.\",\n      \"method\": \"Ex vivo monocyte stimulation with monoclonal anti-PF4/heparin antibody (KKO) and HIT patient plasma, TF expression assays, microparticle quantification, FcγRI blocking, MEK1-ERK1/2 pathway inhibition\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — specific receptor and signaling pathway identified by blocking/inhibition, validated with both monoclonal antibody and patient sera\",\n      \"pmids\": [\"22394597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PF4/heparin complexes are T cell-dependent antigens. Euthymic mice immunized with mPF4/heparin complexes (but not mPF4 or heparin alone) developed heparin-dependent autoantibodies with HIT-like characteristics; athymic mice did not develop these antibodies.\",\n      \"method\": \"Murine immunization model, euthymic vs. athymic mice comparison, platelet activation assay, antibody binding assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic model (athymic mice), antigen specificity controls, functional antibody characterization\",\n      \"pmids\": [\"15845897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CD4 T cells are required for production of PF4/heparin-specific antibodies. Depletion of CD4 T cells markedly impaired PF4/heparin-specific antibody induction; reconstitution experiments showed T-cell help is necessary; B cells lacking CD40 showed markedly reduced PF4/heparin-specific antibody production, demonstrating CD40-dependent T-B cell cooperation.\",\n      \"method\": \"CD4 T-cell depletion with anti-CD4 antibody, Rag1−/− reconstitution with B cells ± T cells, B cell-specific CD40 knockout mice, ELISA for specific antibodies\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (depletion, KO, reconstitution), mechanistic dissection of T-B cooperation\",\n      \"pmids\": [\"25595736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CXCL4 signaling via CXCR3-B activates Gs proteins, elevates cAMP, and activates p38 MAP kinase. Signaling via chondroitin sulfate proteoglycans involves Src family kinases, Syk, monomeric GTPases (including Rac2), sphingosine kinase 1, and MAP kinase family members, with biphasic kinetics of Rac2 and SphK1 activation in monocytes and neutrophils.\",\n      \"method\": \"Pharmacological inhibitors, kinase activation assays, receptor-specific experiments (CXCR3-B vs. proteoglycan), review/synthesis of multiple experimental studies\",\n      \"journal\": \"European journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — synthesis of multiple experimental studies from the field; individual components each from single studies\",\n      \"pmids\": [\"21295372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CXCL4 induces down-regulation of CC chemokine receptors CCR1, CCR2, and CCR5 on human monocytes through autocrine/paracrine TNF-α release; TNF-α then induces CCL3 and CCL4 secretion (desensitizing CCR1 and CCR5), while CCL2 secretion was TNF-α-independent. This limits monocyte chemotactic migration toward cognate CC chemokine ligands.\",\n      \"method\": \"Flow cytometry for CCR expression, TNF-α neutralization, chemotaxis assays, cytokine measurements, conditioned medium experiments\",\n      \"journal\": \"Innate immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic dissection with neutralization and downstream readouts, single laboratory, multiple methods\",\n      \"pmids\": [\"21088050\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Sphingosine kinase 1 (SphK1) is a central regulator of CXCL4-induced monocyte survival, cytokine expression, and oxygen radical formation. CXCL4 upregulates SphK1 mRNA, induces SphK1 enzyme activity, and causes its translocation to the cell membrane. Pharmacological SphK inhibition and SphK1-specific siRNA reversed CXCL4-induced monocyte survival, cytokine expression, and ROS release; the anti-apoptotic effect involves SphK1-dependent caspase inhibition and Erk activation.\",\n      \"method\": \"SphK activity assay, SphK1 membrane translocation assay, pharmacological SphK inhibitor, siRNA knockdown, apoptosis/caspase assays, cytokine and ROS measurements\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — enzyme activity, translocation, siRNA confirmation, pharmacological inhibition; single laboratory, multiple orthogonal methods\",\n      \"pmids\": [\"20104488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CXCL4 protects the antimicrobial peptide LL-37 from cleavage by mast cell beta-tryptase. CXCL4 does not directly inhibit beta-tryptase but destabilizes active tetrameric beta-tryptase by antagonizing the heparin component required for tetramer integrity, thereby acting as a counter-regulator of tryptase activity.\",\n      \"method\": \"In vitro protease cleavage assays, inhibitor studies, comparison of tryptase tetramer stability, bactericidal/functional assays of LL-37 fragments\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzyme assay with mechanistic dissection (heparin competition), single laboratory\",\n      \"pmids\": [\"19625657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Brain microglia express CXCL4 in vitro and in vivo under neurodegenerating conditions. CXCL4-induced microglial migration is absent in CXCR3-deficient microglia, indicating CXCR3 mediates this response. CXCL4 also attenuates LPS-induced microglial phagocytosis and nitric oxide production.\",\n      \"method\": \"In vitro microglia culture, CXCR3−/− microglia migration assays, in vivo immunohistochemistry, phagocytosis and NO production assays\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO for receptor identification, multiple functional readouts, single laboratory\",\n      \"pmids\": [\"18248618\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Platelet secretion of CXCL4 in sepsis is Rac1-dependent. Rac1 inhibitor NSC23766 decreased CLP-enhanced plasma CXCL4 by 77% and abolished PAR4 agonist-induced CXCL4 secretion from isolated platelets. CXCL4 promotes neutrophil accumulation in the lung indirectly by inducing CXCL2 production from alveolar macrophages; CXCL4 itself did not directly drive neutrophil chemotaxis in vitro.\",\n      \"method\": \"Murine CLP sepsis model, Rac1 inhibitor, platelet depletion, ELISA for CXCL4/CXCL2, CXCR2 antagonist, in vitro neutrophil chemotaxis assay, alveolar macrophage stimulation\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection of secretion mechanism and downstream pathway, in vivo and in vitro validation, single laboratory\",\n      \"pmids\": [\"26478565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"C5a activation of C5aR1 on platelets drives preferential release of CXCL4 as an antiangiogenic effector molecule. Platelet-specific deletion of C5aR1 produced a proangiogenic phenotype; interfering with the C5aR1-CXCL4 axis reversed the antiangiogenic effect of platelets both in vitro and in vivo.\",\n      \"method\": \"C5ar1−/− mice, platelet-specific C5aR1 deletion, in vitro endothelial cell migration and tube formation assays, in vivo vascularization models, CXCL4 measurement\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — platelet-specific genetic KO, multiple in vitro and in vivo functional assays, mechanistic axis identified\",\n      \"pmids\": [\"34099640\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CXCL4 binds glycosaminoglycan (GAG) sugars on proteoglycans within the endothelial extracellular matrix, resulting in increased leukocyte adhesion, increased vascular permeability, and non-specific recruitment of a range of leukocytes independent of classical chemokine receptors. GAG sulfation confers selectivity onto chemokine localization.\",\n      \"method\": \"Biophysical binding assays, in vitro leukocyte adhesion and vascular permeability assays, in vivo leukocyte recruitment, GAG-binding mutants\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — biophysical, in vitro, and in vivo methods combined, receptor-independent mechanism demonstrated\",\n      \"pmids\": [\"36640356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In human monocytes/macrophages, costimulation by CXCL4 and TLR8 synergistically activates TBK1 and IKKε, repurposes these kinases toward inflammatory response via coupling with IRF5, and activates the NLRP3 inflammasome. CXCL4 + TLR8 costimulation induces chromatin remodeling and activates de novo enhancers associated with inflammatory genes, selectively amplifying IL-1β production while partially attenuating the interferon response.\",\n      \"method\": \"Kinase activation assays (TBK1, IKKε), IRF5 coupling assays, NLRP3 inflammasome activation, epigenomic profiling (ATAC-seq/ChIP), gene expression analysis, IL-1β ELISA\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — mechanistic pathway dissection with multiple orthogonal methods including epigenomics, kinase activation, and inflammasome assays\",\n      \"pmids\": [\"35701499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PF4 binds and activates the thrombopoietin receptor c-Mpl on platelets, leading to JAK2 activation and phosphorylation of STAT3 and STAT5, resulting in platelet aggregation. Inhibition of the c-Mpl-JAK2 pathway inhibits platelet aggregation induced by PF4 alone, VITT sera, and PF4 combined with VITT IgG. PF4-based immune complexes activate platelets through both FcγRIIA (Fc domain) and c-Mpl (PF4 domain).\",\n      \"method\": \"Binding assays (PF4 to c-Mpl), JAK2/STAT3/STAT5 phosphorylation assays, c-Mpl-JAK2 pathway inhibition, platelet aggregation assays with VITT sera and patient IgG\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — receptor binding, downstream signaling cascade defined, pharmacological inhibition, patient-derived functional validation\",\n      \"pmids\": [\"37883794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCL4 forms heterodimers with CXCL12; the CXCL4-CXCL12 binding interface was identified by NMR spectroscopy. CXCL4-CXCL12 heterodimers inhibit CXCL12-driven breast cancer cell migration via CXCR4. A CXCL4-derived peptide mimicking the binding interface reproduced this inhibitory activity.\",\n      \"method\": \"NMR spectroscopy (binding interface mapping), cell migration assays (MDA-MB-231), CXCR4 blocking, CXCL4-derived peptide functional assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural mapping of binding interface, functional validation in migration assay, single laboratory\",\n      \"pmids\": [\"31785332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"PF4 inhibits human megakaryocytopoiesis in vitro with lineage specificity (no effect on myeloid or erythroid colony formation). Inhibition was mediated through impeding megakaryocyte maturation rather than proliferation. A synthetic 24-residue COOH-terminal PF4 peptide reproduced this effect and decreased Factor V mRNA expression in individual megakaryocytes (~60% reduction).\",\n      \"method\": \"Megakaryocyte colony formation assay, cell maturation analysis, in situ hybridization for Factor V mRNA in single cells, comparison with beta-thromboglobulin peptides\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — lineage-specific inhibition, mechanistic dissection (maturation vs. proliferation), peptide domain mapping, single laboratory\",\n      \"pmids\": [\"2523411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CXCL4 and CXCR2 regulate survival and self-renewal of hematopoietic stem/progenitor cells. CXCL4 knockdown in human CD34+ cells significantly decreased viability and colony-forming potential. Cxcl4−/− mice showed decreased HSC numbers and reduced self-renewal capacity after secondary transplantation, demonstrating an autocrine/paracrine role of CXCL4 in HSC maintenance.\",\n      \"method\": \"siRNA knockdown in human CD34+ cells, Cxcl4−/− mouse model, serial transplantation assays, flow cytometry for HSC subpopulations, colony formation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO, human cell knockdown, serial transplantation; multiple orthogonal methods, two species\",\n      \"pmids\": [\"27222476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Polyreactive natural IgM initiates complement activation by PF4/heparin complexes through the classical complement pathway. Plasma IgM levels correlated with complement activation (r=0.898). IgM depletion abrogated C3c generation. Monoclonal polyreactive IgM and cord blood IgM generated C3c in the presence of PF4/heparin. Anti-C1q antibody prevented IgM-mediated complement activation, confirming classical pathway involvement.\",\n      \"method\": \"Proteomic correlation analysis, IgM depletion experiments, cord blood IgM, monoclonal polyreactive IgM, anti-C1q blocking, C3c generation assay, B-cell deposition assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (depletion, blocking, reconstitution), mechanistic pathway (classical complement) defined, replicated across donor plasmas\",\n      \"pmids\": [\"30309891\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Cxcl4 genetic deletion in mice significantly reduced liver fibrosis after CCl4 and thioacetamide-induced chronic injury, decreased infiltration of neutrophils and CD8+ T cells, and was associated with changes in fibrosis-related gene expression (Timp-1, Mmp9, Tgf-β, IL-10). In vitro, recombinant Cxcl4 stimulated proliferation, chemotaxis, and chemokine expression of hepatic stellate cells.\",\n      \"method\": \"Cxcl4−/− mice in two injury models, histological/biochemical analysis, FACS for infiltrating immune cells, in vitro hepatic stellate cell assays, gene expression analysis\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO in two independent injury models, in vitro mechanistic validation in target cells, multiple orthogonal readouts\",\n      \"pmids\": [\"20162727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CXCL4 directly induces myofibroblast differentiation and collagen synthesis in fibroblast precursors and endothelial cells (through endothelial-to-mesenchymal transition). CXCL4-deficient mice showed reduced fibrosis in skin, lungs, and heart; overexpressing human CXCL4 in mice aggravated bleomycin-induced fibrosis; blocking CXCL4 reduced fibrosis.\",\n      \"method\": \"Cxcl4−/− mice (multiple fibrotic models), human CXCL4 overexpression mouse model, CXCL4 blocking, in vitro myofibroblast differentiation and collagen synthesis assays, single-cell ligand-receptor analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO, gain-of-function overexpression, pharmacological blocking, in vitro mechanistic validation, multiple organ systems\",\n      \"pmids\": [\"34986347\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CXCL4 activates the p38-MAPK pathway through CXCR3, leading to upregulation of p53 and Bax and subsequent caspase-8, -9, and -3 activation in intestinal epithelial cells (IEC-6), mediating 5-FU-induced intestinal apoptosis. Neutralizing anti-CXCL4 antibody reduced p53 and Bax expression and crypt epithelial apoptosis in vivo.\",\n      \"method\": \"In vivo 5-FU mucositis mouse model, anti-CXCL4 neutralizing antibody, in vitro IEC-6 signaling (p38-MAPK phosphorylation, p53/Bax expression, caspase activation), CXCR3 receptor identification\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — signaling cascade defined in vitro with pharmacological validation, confirmed in vivo with neutralizing antibody, single laboratory\",\n      \"pmids\": [\"24800927\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CXCL4 assembles RNA (in addition to DNA) into complexes that protect RNA from enzymatic degradation and persist in vivo in SSc plasma. CXCL4-RNA complexes stimulate monocyte-derived DCs to produce TNF-α, IL-12, IL-23, IL-8, and pro-collagen in a predominantly TLR7/8-dependent, CXCR3-independent manner.\",\n      \"method\": \"CXCL4-RNA complex detection in SSc patient plasma, RNase protection assays, in vitro MDDC stimulation, TLR7/8 blocking, CXCR3 blocking, cytokine/collagen measurement\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro mechanistic dissection with receptor blocking, in vivo complex detection in patients, single laboratory\",\n      \"pmids\": [\"36614095\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CXCL4 links inflammation to fibrosis by reprogramming monocyte-derived dendritic cells through key transcriptional regulator CIITA. Inhibition of CIITA mimicked CXCL4's pro-inflammatory/pro-fibrotic phenotype. CXCL4-exposed dendritic cells produce extracellular matrix molecules and induce myofibroblast differentiation.\",\n      \"method\": \"Transcriptomic and methylation profiling (65 longitudinal profiles), gene regulatory network analysis, CIITA inhibition, in vitro myofibroblast differentiation assay, ECM production measurement\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systems-level analysis validated by CIITA inhibition experiments and functional assays, single laboratory\",\n      \"pmids\": [\"33042127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CXCL4 production by pDCs in SSc is driven by simultaneous exposure to hypoxia and TLR9 activation, dependent on mitochondrial reactive oxygen species (mtROS) overproduction leading to stabilization of HIF-2α. Blocking either mtROS or HIF-2α pathways attenuated CXCL4 production.\",\n      \"method\": \"pDC culture under hypoxia ± TLR agonists, mtROS inhibition, HIF-1α/HIF-2α expression and stabilization assays (ELISA, qPCR, FACS, Western blot), umbilical cord CD34-derived pDC validation\",\n      \"journal\": \"Rheumatology (Oxford)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods, pathway inhibitor validation, single laboratory\",\n      \"pmids\": [\"34559222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CXCL4 triggers monocytes and macrophages to produce PDGF-BB, which then activates dermal fibroblasts to produce extracellular matrix and inflammatory mediators. This indirect fibroblast activation was abrogated by PDGF-receptor inhibition (Crenolanib or siRNA). TLR ligands, IFNα, and TGFβ did not induce PDGF-BB release in contrast to CXCL4.\",\n      \"method\": \"Multiplex immunoassay for cytokines, PDGF-BB quantification (immunoassay, Western blot), siRNA PDGF-receptor knockdown, Crenolanib inhibition, fibroblast ECM and cytokine production assays\",\n      \"journal\": \"Journal of autoimmunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway from CXCL4→PDGF-BB→fibroblast activation defined, pharmacological and genetic blocking, single laboratory\",\n      \"pmids\": [\"32284212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CXCL4 infusion impaired macrophage phagocytic capacity by reducing CD36 levels through MMP-9-dependent and -independent signaling, leading to higher post-MI mortality and LV dilation. In vitro, a CD36 neutralizing antibody inhibited phagocytosis similarly to CXCL4, and combination of CXCL4 + CD36Ab had no additive effect, establishing CXCL4 acts through CD36 signaling.\",\n      \"method\": \"In vivo CXCL4 mini-pump infusion post-MI, echocardiography, ex vivo and in vitro phagocytosis assays, CD36 neutralizing antibody, MMP-9 measurement, gene expression analysis\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro mechanistic dissection, receptor identified by non-additivity experiment, single laboratory\",\n      \"pmids\": [\"30169632\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1975,\n      \"finding\": \"PF4 (platelet factor 4) is a heat-stable heparin-neutralizing protein purified from human platelets; its antiheparin activity and antigenicity are destroyed by trypsin; PF4 forms a complex with heparin that shifts its electrophoretic migration from cathodal to anodal, indicating charge neutralization.\",\n      \"method\": \"SDS-PAGE, immunodiffusion, immunoelectrophoresis with monospecific antibody, heparin-neutralization assay, trypsin digestion, antibody inhibition of antiheparin activity\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biochemical characterization with purified protein, multiple complementary methods, foundational study\",\n      \"pmids\": [\"803847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Platelets are activated by exercise and are required for exercise-induced hippocampal precursor cell proliferation in aged mice. The platelet-derived exerkine CXCL4/PF4 ameliorates age-related regenerative and cognitive impairments in a hippocampal neurogenesis-dependent manner when administered systemically.\",\n      \"method\": \"Platelet depletion during exercise, aged mouse model, hippocampal precursor cell proliferation assay, systemic CXCL4 injection, hippocampal neurogenesis-dependent cognitive testing\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — platelet depletion and CXCL4 injection with neurogenesis-dependent functional readout, single laboratory\",\n      \"pmids\": [\"37587147\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PF4/CXCL4 is a highly cationic CXC chemokine stored in platelet α-granules and secreted upon PKC-dependent platelet activation (regulated by Rac1); it forms tetramers that assemble with heparin or other polyanions into ultralarge antigenic complexes (central to HIT pathogenesis via FcγRIIA- and c-Mpl/JAK2-mediated platelet activation); it binds cell-surface glycosaminoglycans (chondroitin sulfate proteoglycans) and integrins (αvβ3, αvβ5, α5β1) to exert context-dependent effects including macrophage differentiation to a unique CD163-negative 'M4' phenotype, induction of monocyte survival and pro-fibrotic PDGF-BB release, direct myofibroblast differentiation and collagen synthesis, inhibition of angiogenesis, regulation of HSC quiescence via megakaryocyte-derived secretion, induction of neutrophil accumulation through indirect CXCL2 generation in macrophages, amplification of TLR9 and TLR8 innate immune responses by forming liquid-crystalline DNA/RNA complexes, and inhibition of T cell-mediated immune responses through CXCR3-dependent suppression of CD8+ T cells; its transcription in megakaryocytes is directly regulated by RUNX1 (binding −1774 and −157 promoter sites) and by USF1/USF2 (binding E-box/TME elements), and its production in pDCs is driven by hypoxia+TLR9 costimulation via mtROS-HIF-2α stabilization.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PF4/CXCL4 is a highly cationic, heparin-neutralizing CXC chemokine stored in platelet secretory granules whose biological output is dominated by its capacity to bind polyanions and assemble into multivalent complexes that drive immune, hematopoietic, fibrotic, and vascular responses [#37, #0, #3]. As a foundational property, PF4 forms charge-neutralizing complexes with heparin [#37], and intact PF4 tetramers assemble with unfractionated heparin into ultralarge (>670 kDa) complexes over a narrow molar ratio that are the principal antigenic targets in heparin-induced thrombocytopenia and drive Fc\\u03b3RIIA-dependent platelet activation [#0]. These complexes behave as T cell-dependent antigens requiring CD4 T-cell help and CD40-dependent T-B cooperation [#13, #14], and the resulting PF4/heparin antibodies propagate thrombotic signaling by inducing monocyte tissue factor via Fc\\u03b3RI-MEK1-ERK1/2 [#12], engaging Fc\\u03b3RIIA on neutrophils bound to surface chondroitin sulfate [#11], and triggering classical-pathway complement activation through polyreactive natural IgM [#28]; PF4 itself also activates platelets directly by binding the thrombopoietin receptor c-Mpl, activating JAK2 and STAT3/STAT5 [#24]. Beyond complex formation, secreted PF4 acts through multiple cell-surface platforms: cell-surface glycosaminoglycans and chondroitin sulfate proteoglycans [#7, #11, #22], integrins \\u03b1v\\u03b23/\\u03b1v\\u03b25/\\u03b15\\u03b21 on endothelium where soluble PF4 inhibits adhesion and angiogenesis [#10, #21], the GPCRs CXCR3 and CCR1 [#9, #8], and CD36 on macrophages [#36]. Through these receptors PF4 reprograms myeloid cells\\u2014downregulating CD163 on macrophages [#7], driving monocyte survival and cytokine output via sphingosine kinase 1 [#17], and synergizing with TLR8 to activate TBK1/IKK\\u03b5-IRF5 and the NLRP3 inflammasome [#23]\\u2014and organizes self- and microbial DNA and RNA into liquid-crystalline complexes that amplify TLR9 and TLR7/8 responses in dendritic cells, a mechanism central to systemic sclerosis pathology [#6, #32]. PF4 is a potent pro-fibrotic effector, directly inducing myofibroblast differentiation and collagen synthesis and promoting fibrosis across skin, lung, heart, and liver [#30, #29], partly via monocyte-derived PDGF-BB [#35]. As a megakaryocyte- and platelet-derived niche factor it enforces HSC quiescence and supports HSC self-renewal [#2, #27]. Megakaryocytic PF4 transcription is directly controlled by RUNX1 and by USF1/USF2 acting on E-box/TME promoter elements [#4, #5].\",\n  \"teleology\": [\n    {\n      \"year\": 1975,\n      \"claim\": \"Established PF4's defining biochemical identity as a heparin-neutralizing platelet protein, framing all later polyanion-driven mechanisms.\",\n      \"evidence\": \"Purification from human platelets with immunoelectrophoresis, heparin-neutralization assay, and trypsin digestion\",\n      \"pmids\": [\"803847\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural basis for tetramerization or heparin binding defined\", \"Cellular receptors not yet identified\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Showed PF4 has lineage-specific autoregulatory effects on its own producer lineage, inhibiting megakaryocyte maturation.\",\n      \"evidence\": \"Megakaryocyte colony formation assays, in situ hybridization for Factor V mRNA, COOH-terminal peptide mapping\",\n      \"pmids\": [\"2523411\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor mediating the inhibition not identified\", \"Relationship to later HSC quiescence role unestablished\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified MMP-9 as a protease that degrades PF4, distinguishing its regulation from other chemokines and indicating proteolytic turnover.\",\n      \"evidence\": \"In vitro proteolysis assay with purified neutrophil progelatinase B activated by stromelysin-1\",\n      \"pmids\": [\"11023497\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cleavage sites and biological consequences of fragments not defined\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined the molecular requirements for the antigenic PF4/heparin complex in HIT, explaining why only certain heparins and intact tetramers are pathogenic.\",\n      \"evidence\": \"Electron microscopy, size-exclusion chromatography, PF4 tetramerization mutagenesis, platelet activation and antibody-binding assays; plus identification of USF1/USF2 transcriptional control\",\n      \"pmids\": [\"15304392\", \"15187018\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural model of ultralarge complex not resolved\", \"Determinants of the conformational neoepitope not fully mapped\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Established that PF4/heparin complexes are T cell-dependent antigens and revealed receptor-specific opposing effects on T helper differentiation via CXCR3 isoforms.\",\n      \"evidence\": \"Euthymic vs athymic mouse immunization; T-cell line cytokine, promoter, and CXCR3-blocking assays\",\n      \"pmids\": [\"15845897\", \"16337473\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CXCR3-A vs CXCR3-B signaling divergence shown in single laboratory\", \"In vivo relevance of TH2 skewing not established\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Distinguished regulated, PKC-dependent secretion of CXCL4 from constitutive secretion of its variant CXCL4L1, defining how PF4 release is controlled.\",\n      \"evidence\": \"Transfection of multiple cell types, subcellular fractionation, PKC stimulation and secretion assays\",\n      \"pmids\": [\"17218382\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Granule sorting determinants not identified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected PF4 to organ fibrosis and dissected myeloid signaling, showing genetic deletion reduces liver fibrosis and that PF4 modulates monocyte chemokine receptors and survival pathways.\",\n      \"evidence\": \"Cxcl4\\u2212/\\u2212 mice in two liver injury models; monocyte CCR downregulation via autocrine TNF-\\u03b1; SphK1 enzyme/translocation/siRNA studies; CXCR3-dependent microglial migration\",\n      \"pmids\": [\"20162727\", \"21088050\", \"20104488\", \"18248618\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct fibroblast receptor for PF4 not identified at this stage\", \"SphK1 and TNF-\\u03b1 pathways each from single laboratory\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identified RUNX1 as a direct transcriptional driver of PF4 in megakaryocytes and outlined the dual CXCR3-B/proteoglycan signaling architecture.\",\n      \"evidence\": \"ChIP, EMSA, reporter mutagenesis, RUNX1 knockdown/overexpression; synthesis of CXCR3-B (Gs/cAMP/p38) and proteoglycan (Src/Syk/Rac2/SphK1) signaling\",\n      \"pmids\": [\"21129147\", \"21295372\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling synthesis aggregates components from disparate single studies\", \"Interplay between transcriptional regulators not fully mapped\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Provided a mechanism for HIT thrombosis by showing antibody complexes drive monocyte tissue factor expression through Fc\\u03b3RI and MEK1-ERK1/2.\",\n      \"evidence\": \"Ex vivo monocyte stimulation with KKO and patient plasma, TF and microparticle assays, Fc\\u03b3RI blocking, MEK inhibition\",\n      \"pmids\": [\"22394597\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of monocyte vs platelet procoagulant activity in vivo not quantified\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified megakaryocyte-derived CXCL4 as a niche signal enforcing HSC quiescence, linking platelet biology to stem cell regulation.\",\n      \"evidence\": \"In vivo CXCL4 injection, Cxcl4\\u2212/\\u2212 mice, MK depletion, 3D whole-mount imaging; plus CXCR3/p38-p53-Bax apoptotic cascade in intestinal epithelium\",\n      \"pmids\": [\"25326802\", \"24800927\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"HSC receptor for CXCL4 quiescence signal not defined\", \"Reconciliation of quiescence-promoting vs self-renewal roles incomplete\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated an autocrine/paracrine requirement for CXCL4 in HSPC survival and self-renewal, complementing the niche quiescence role.\",\n      \"evidence\": \"siRNA knockdown in human CD34+ cells, Cxcl4\\u2212/\\u2212 mice, serial transplantation, colony assays\",\n      \"pmids\": [\"27222476\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CXCR2 mechanistic role in HSPCs not fully resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Expanded the PF4 receptor repertoire and innate-immune amplifying functions: CCR1 agonism for monocyte chemotaxis and TLR8 synergy driving inflammasome and enhancer remodeling.\",\n      \"evidence\": \"Chemotaxis/calcium/PTX/chondroitinase/CCR1-transfectant assays; kinase, IRF5, NLRP3, and ATAC/ChIP epigenomic profiling; CD4 T-cell/CD40 dependence of antibody production\",\n      \"pmids\": [\"29930254\", \"35701499\", \"25595736\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How GAG presentation couples to CCR1 activation not structurally defined\", \"Endogenous TLR8 ligand context in vivo not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined PF4 as a nucleic-acid-organizing scaffold that amplifies TLR9 responses, and mapped its heterodimerization with CXCL12 controlling cancer cell migration.\",\n      \"evidence\": \"Biophysical liquid-crystalline complex assays, pDC stimulation, CXCR3-independence; NMR interface mapping with CXCL12 and migration assays; CD36-dependent macrophage phagocytosis post-MI\",\n      \"pmids\": [\"31043596\", \"31785332\", \"30169632\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor sensing the liquid-crystalline complex beyond endosomal TLR9 not defined\", \"CD36 mechanism shown in single laboratory\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established PF4 as a direct pro-fibrotic effector across multiple organs and dissected the monocyte-PDGF-BB and CIITA/DC reprogramming routes to fibrosis.\",\n      \"evidence\": \"Cxcl4\\u2212/\\u2212 and human CXCL4 overexpression mice in multiple fibrotic models, blocking, in vitro myofibroblast differentiation; PDGF-BB and CIITA pathway dissection\",\n      \"pmids\": [\"34986347\", \"32284212\", \"33042127\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct fibroblast/endothelial receptor mediating myofibroblast differentiation not identified\", \"PDGF-BB and CIITA routes each from single laboratory\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Resolved how endothelial GAG sulfation tunes PF4-driven, receptor-independent leukocyte recruitment, extended nucleic-acid sensing to RNA, and revealed a beneficial neurogenic exerkine role.\",\n      \"evidence\": \"Biophysical GAG-binding/mutant studies with leukocyte adhesion and permeability assays; CXCL4-RNA RNase protection and TLR7/8-dependent DC stimulation; platelet depletion and CXCL4 injection in aged mice\",\n      \"pmids\": [\"36640356\", \"36614095\", \"37587147\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor for hippocampal neurogenic effect not identified\", \"RNA-complex mechanism from single laboratory\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identified c-Mpl/JAK2 as a direct PF4 platelet-activating receptor axis, unifying VITT and HIT platelet activation through dual Fc\\u03b3RIIA and c-Mpl engagement.\",\n      \"evidence\": \"PF4-c-Mpl binding, JAK2/STAT3/STAT5 phosphorylation, pathway inhibition, platelet aggregation with VITT sera and patient IgG\",\n      \"pmids\": [\"37883794\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of PF4 binding to c-Mpl not resolved\", \"Relative contribution of c-Mpl vs Fc\\u03b3RIIA in vivo not quantified\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The direct cell-surface receptor(s) mediating PF4-induced myofibroblast differentiation, HSC quiescence, and neuro-regenerative effects remain unidentified, and a unified structural model linking polyanion-complex assembly to the distinct receptor systems is lacking.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No defined receptor for the direct pro-fibrotic effect\", \"No structural model connecting tetramer/complex states to integrin, CXCR3, CCR1, c-Mpl, and CD36 engagement\", \"Endogenous physiological versus pathological balance of PF4 functions undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [8, 9, 24]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [0, 6, 32, 37]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [18, 37]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [8, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [3, 22]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 12, 23, 28]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [0, 24, 37]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 9, 17, 24]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 24, 29, 30]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [4, 5]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CXCR3\", \"CCR1\", \"MPL\", \"CXCL12\", \"ITGAV\", \"ITGB3\", \"CD36\", \"FCGR2A\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}